University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2022

Characterizing And Quantifying The Redox Behavior Of Cytokine
Hmgb1 In Drug-Induced Liver Injury Via High Resolution Mass
Spectrometry
Ross Pirnie
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Analytical Chemistry Commons, and the Pharmacology Commons

Recommended Citation
Pirnie, Ross, "Characterizing And Quantifying The Redox Behavior Of Cytokine Hmgb1 In Drug-Induced
Liver Injury Via High Resolution Mass Spectrometry" (2022). Publicly Accessible Penn Dissertations.
5235.
https://repository.upenn.edu/edissertations/5235

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/5235
For more information, please contact repository@pobox.upenn.edu.

Characterizing And Quantifying The Redox Behavior Of Cytokine Hmgb1 In DrugInduced Liver Injury Via High Resolution Mass Spectrometry
Abstract
High mobility group box 1 (HMGB1) is a protein that is released in several pathological contexts, including
acetaminophen (APAP) overdose, and modulates the subsequent immune response to tissue damage.
Oxidation of HMGB1 potentially regulates its interactions with the immune system but there have been a
number of contradictory studies on the redox behavior of HMGB1 and what proteoforms of HMGB1 are
present in oxidative pathology. Therefore, a stable isotope dilution two-dimensional nano-ultrahighperformance liquid chromatography parallel reaction monitoring/high-resolution mass spectrometry (2Dnano-UHPLC-PRM/HRMS) method was developed along with a hepatocarcinoma cell model of APAP
overdose to allow for characterization of HMGB1 redox behavior during APAP toxicity. Oxidative
modifications to cysteine (Cys) residues (Cys-23, Cys-45, and Cys-106) that are present in HMGB1 were
characterized and quantified using carbamidoethyl (CAE) derivatization before and after reduction as well
as by direct analysis of disulfide cross-linked peptides. A stable isotope labeled form of HMGB1 was used
as an internal standard to correct for sample-to-sample differences in immunoaffinity precipitation (IP),
derivatization, and electrospray ionization. The metabolism, toxicity and release of HMGB1 in response to
APAP were characterized in a cell model of APAP overdose. Four discreet HMGB1 proteoforms were
found to be released from cells following a 24-hour exposure to toxic levels of APAP. Reduced HMGB1
with all three Cys-residues in their free thiol state accounted for 18% of the secreted HMGB1. The
proteoform with disulfide between Cys-23 and Cys-45 accounted for 24% of the HMGB1. No evidence was
obtained for a disulfide cross-link between Cys-106 and the other two Cys-residues. However, 45% of the
HMGB1 formed a cross-link with unidentified intracellular proteins via an intermolecular disulfide bond
and 12% was present as cysteic acid. Secreted plasma HMGB1 Cys-23/Cys45 disulfide proteoform
together with the Cys-106/protein disulfide proteoforms could potentially serve as early biomarkers of
hepatoxicity after APAP overdose as well as biomarkers of drug-induced liver injury (DILI).
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ABSTRACT
CHARACTERIZING AND QUANTIFYING THE REDOX BEHAVIOR OF THE
CYTOKINE HMGB1 IN DRUG-INDUCED LIVER INJURY VIA HIGH
RESOLUTION MASS SPECTROMETRY
Ross Pirnie
Ian A. Blair
High mobility group box 1 (HMGB1) is a protein that is released in several
pathological contexts, including acetaminophen (APAP) overdose, and modulates
the subsequent immune response to tissue damage. Oxidation of HMGB1
potentially regulates its interactions with the immune system but there have been
a number of contradictory studies on the redox behavior of HMGB1 and what
proteoforms of HMGB1 are present in oxidative pathology. Therefore, a stable
isotope

dilution

two-dimensional

nano-ultrahigh-performance

liquid

chromatography parallel reaction monitoring/high-resolution mass spectrometry
(2D-nano-UHPLC-PRM/HRMS)

method

was

developed

along

with

a

hepatocarcinoma cell model of APAP overdose to allow for characterization of
HMGB1 redox behavior during APAP toxicity. Oxidative modifications to cysteine
(Cys) residues (Cys-23, Cys-45, and Cys-106) that are present in HMGB1 were
characterized and quantified using carbamidoethyl (CAE) derivatization before and
after reduction as well as by direct analysis of disulfide cross-linked peptides. A
stable isotope labeled form of HMGB1 was used as an internal standard to correct
for

sample-to-sample

differences

in
iii

immunoaffinity

precipitation

(IP),

derivatization, and electrospray ionization. The metabolism, toxicity and release of
HMGB1 in response to APAP were characterized in a cell model of APAP
overdose. Four discreet HMGB1 proteoforms were found to be released from cells
following a 24-hour exposure to toxic levels of APAP. Reduced HMGB1 with all
three Cys-residues in their free thiol state accounted for 18% of the secreted
HMGB1. The proteoform with disulfide between Cys-23 and Cys-45 accounted for
24% of the HMGB1. No evidence was obtained for a disulfide cross-link between
Cys-106 and the other two Cys-residues. However, 45% of the HMGB1 formed a
cross-link with unidentified intracellular proteins via an intermolecular disulfide
bond and 12% was present as cysteic acid. Secreted plasma HMGB1 Cys23/Cys45 disulfide proteoform together with the Cys-106/protein disulfide
proteoforms could potentially serve as early biomarkers of hepatoxicity after APAP
overdose as well as biomarkers of drug-induced liver injury (DILI).
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CHAPTER 1: Introduction
1a. High Mobility Group Box 1 (HMGB1) Background
1a1. History of HMGB1
The high-mobility group (HMG) is comprised of three superfamilies of
chromosomal proteins, each with a unique functional domain that allows for
differential binding to DNA or DNA associated proteins. HMG proteins were first
identified in the 1960’s as abundant non-histone proteins that appeared in histone
fractions of calf thymus1. The HMGB superfamily contains 4 proteins, each with an
HMG-box domain that facilitates DNA binding. HMGB1 was first isolated and
characterized in 1987 when it was observed to bind heparin and induce neuron
outgrowth activity2. Initially dubbed “p30” for its apparent molecular weight as
determined by gel electrophoresis, its sequence was deduced shortly thereafter by
nucleotide sequencing3. Interestingly, from the first publication identifying p30, or
HMGB1, the potential for HMGB1 to undergo oxidative changes was noted.
Specifically, it was observed that HMGB1 migrates differently under reducing and
non-reducing gel electrophoresis conditions and forms a presumed dimer in the
latter, indicating intramolecular and intermolecular disulfide bonds are possible2.
Shortly after its discovery and sequencing, HMGB1 was found to be nearly
ubiquitously expressed in eukaryotic cells4. HMGB1 is highly conserved and found
in the nucleus and cytoplasm of almost all mammalian cell types, indicating its
critical role in regulation of transcription. The importance of HMGB1 is such that
knockout of HMGB1 expression is lethal in newborn animals5. Shortly after its
1

identification, HMGB1 was discovered to function outside of the nucleus in
response to stress, tissue damage or infection6. There is therefore a long history
of investigating HMGB1’s role in the immune response to sepsis and other
pathological conditions. Over the past several decades, there has been significant
investigation into the contribution of HMGB1 to a range of pathological conditions,
including, cancer, autoimmune disease, sepsis, infection and inflammation 7-10.
Despite this long history of investigation, the extracellular function of HMGB1 is
still an active area of investigation with considerable literature attention dedicated
towards it.
1a2. Structural Properties of HMGB1
HMGB1 is composed of 216 amino acids, comprising three distinct
functional domains known as the A-box (amino acids 9-85), B-box (amino acids
88-162) and acidic tail (amino acids 187-215) (Figure 1a.1)11. The A- and B-boxes
are both composed of three alpha helixes and are highly positively charged. The
acidic tail of HMGB1 is composed entirely of aspartic and glutamic acid residues,
resulting in a strong negative charge that allows interaction with the A- and B-box12.

2

Figure 1a1. Sequence and structure of HMGB1 with domains highlighted

Within the nucleus, all three domains are important for DNA-binding. The A- and
B-box of HMGB1 are both “HMG-boxes”; novel sequence and structural motifs that
facilitate DNA-binding in several HMG and non-HMG proteins13. HMG-boxes have
a characteristic strong positive charge that allows for sequence-independent
interaction with the negatively charged DNA. The three alpha helixes in an HMGbox form a characteristic L-shaped structure with an approximate angle of 80 o,
allowing for preferential binding to bent DNA as well as four-way DNA junctions11.
The A-box and B-box of HMGB1 are highly similar in structure but differences in
sequence do impart small structural differences between the two; for instance, the
angle between arms of the characteristic L-shape differ slightly and may result in
slightly different DNA-binding activity14. The acidic tail of HMGB1 regulates HMGbox binding and enhances HMGB1 selectivity for bent DNA by interacting with the
3

positively charged N-terminal region, effectively masking the DNA-binding regions
of HMGB1. The acidic tail interaction with the DNA-binding regions is stronger than
that of interactions between DNA-binding regions and linear DNA but weaker than
that of DNA-binding regions and bent DNA, imparting additional selectivity for bent
DNA12.
HMGB1 has three highly conserved, oxidation-sensitive cysteine (Cys)
residues at amino acid positions 23, 45 and 106. Cysteine residues are highly
susceptible to oxidative modifications including disulfide bonds that can induce
large structural changes. The positioning of Cys-23 and Cys-45 within the A-box
of HMGB1 as well as the positioning of Cys-106 within the B-box create the
potential for disulfide formation within these regions that potentially lead to large
changes in structure and DNA-binding in response oxidation. Cys-23 and Cys-45
are in close proximity whereas Cys-106 is spatially separated from the other two
(Figure 1a2). HMGB1 contains two purported nuclear localization signals or
sequences (NLS) at amino acids 28-44 (KKKHPDASVNFSEFSKK) and 179-185
(EKSKKKK) but the importance of these signals for cellular localization and
HMGB1 secretion are controversial15,16.

4

Figure 1a2. Crystal structure of HMGB1 (PCB 2YRQ) as determined by NMR, the
A-box is labeled in blue, B-Box labeled in green and the acidic tail is labeled in
grey with cysteine residues highlighted in red.

1a3. Intracellular DNA-Bending Function of HMGB1
Within the cell, HMGB1 can be found in both the cytoplasm and the
nucleus17, where it serves a range of functions linked to its DNA-binding abilities.
HMGB1 preferentially binds DNA with unusual bent or distorted structures and as
such, plays a role in the repair of damaged DNA. HMGB1 has, in fact, been
implicated in all the major DNA repair pathways (reviewed in Lange et. al., 2009)18
through two general mechanisms. In the first mechanism, HMGB1 recognizes and
binds distorted DNA and then facilitates repair via recruitment of the necessary
proteins. For example, HMGB1 was found to interact with MutS homolog 2 (MSH2)
and MutL homolog 1 (MLH1) proteins critical for mismatch repair, the apyrimidinic
endonuclease 1 (APE1) and flap endonuclease 1 (FEN) proteins critical for base
5

excision repair and the replication protein A (RPA) protein critical for nucleotide
excision repair19-21. In the second mechanism, HMGB1 binds distorted or damaged
DNA and blocks repair complexes from assembling, ultimately inducing the death
of damaged cells via prevention of requisite transcription. The contribution of either
mechanism in various contexts is still debated but it is clear HMGB1 can and does
play a role in responding to and repairing damaged DNA.
In addition to binding damaged DNA, HMGB1 can bind linear DNA to
regulate transcription and chromatin remodeling. HMGB1 has weak, nonspecific
affinity for linear DNA but interactions with other proteins can indirectly allow
sequence-specific interactions; for instance, HMGB1 interacts with and enhances
the activity of p53 by promoting the assembly of p53 nucleoprotein structures22.
HMGB1 bends DNA by inserting a wedge-shaped, positively charged region into
the minor groove of DNA and these DNA bends then enhance the binding of
proteins like p53 to their gene targets13. Similar interactions have been described
between HMGB1 and targets such as the TATA-binding protein, hormone
receptors and retinoblastoma protein23-25. HMGB1 also plays a role in chromatin
remodeling by facilitating nucleosome sliding. DNA must be separated from
histone proteins for nucleosome sliding to occur and HMGB1 allows this separation
by bending DNA at the entry and exit points of the nucleosome, increasing
flexibility26. HMGB1 therefore not only directly informs DNA expression through its
transcription factor interactions but also dictates the epigenetic structure of DNA
through its interactions with nucleosomes.
6

The intracellular functions of HMGB1 result from its DNA-binding properties
but also of its concentration and mobility within cells. HMGB1 is highly mobile
within the cell and can travel the entire span of the nucleus in less than 1.5
seconds8. Rapid, transient interactions throughout the nucleus allow for near
constant availability of HMGB1 to remodel chromatin and enhance transcription
factor DNA-binding. This availability of HMGB1 is enhanced by its intracellular
concentrations, generally at or above 106 molecules per cell, only about ten times
less than that of the abundant core histone proteins4. The mobility and
concentration of HMGB1 are important for its intracellular functions but also have
important implications for its extracellular functions. In the unregulated release of
intracellular proteins in vivo, those with high mobility and concentration are the
most likely to be found in circulation at meaningful concentrations.
1a4. Secretion and Extracellular Release of HMGB1
HMGB1 in the extracellular environment is a damage-associated molecular
pattern (DAMP) that acts as a danger signal and a cytokine that regulates the
immune response to tissue damage, infection, and sterile inflammation. HMGB1 is
thought to be released into the extracellular environment through one of two
processes: active secretion from immune cells or passive release from damaged
tissue8. HMGB1 lacks a canonical secretion signal sequence and as such, active
secretion does not occur through the classical endoplasmic reticulum-Golgi
vesicular pathway. Instead, HMGB1 is thought to be secreted non-canonically
through secretory lysosomes27. Active HMGB1 secretion from immune cells has
7

been reported to occur through a number of activation signals, including cytokines
such as tumor necrosis factor (TNF-α), bacterial endotoxin and cell-cell crosstalk
between immune cells28-30. The regulation of HMGB1 active secretion is less well
understood and remains a subject of debate in the literature. Post-translational
modifications (PTMs) including phosphorylation, acetylation and methylation have
been proposed to govern and induce HMGB1 secretion but not all modifications
are universally detected in secreted HMGB115,16,31. For instance, acetylation of
HMGB1’s NLS was proposed to be necessary and sufficient for release of HMGB1,
yet work by the Blair Lab showed no evidence of acetylation on circulating
HMGB115,32. The PTMs that control secretion and in which cellular contexts is still
an open question.
HMGB1 release from damaged tissue, unlike that from immune cells,
occurs passively when injured cells lose their membrane integrity during apoptotic
or necrotic cell death. Necrosis is an unregulated form of cell death wherein cell
injury results in loss of membrane integrity and uncontrolled release of intracellular
proteins, including HMGB1, into the extracellular space. Examples of necrotic
pathology where increases in circulating HMGB1 levels have been observed
include myocardial infarction, ischemia, sepsis and drug-induced liver injury33-35.
Contrasting necrosis, apoptosis is a programmed and highly regulated form of cell
death that limits release of intracellular proteins. Some publications have shown a
lack of HMGB1 release following apoptosis in cell models while others have
demonstrated robust release, indicating that apoptotic HMGB1 release is possible
8

but not universal and that HMGB1 release is likely dependent on cell type and
apoptosis inducer8,36. HMGB1 has been shown to bind DNA tightly during
apoptosis so differential HMGB1 intracellular localization between cell types might
explain differential release; cell types with HMGB1 primarily localized to the
cytoplasm will avoid HMGB1-DNA binding that would prevent release21. In models
of apoptosis with HMGB1 release, such release occurs at a late secondary necrotic
stage following DNA condensation and cell shrinkage 30. HMGB1 release in
apoptosis, much like necrosis, is therefore nonspecific leakage following loss of
membrane integrity.
Although HMGB1 is released in vivo in a range of pathological conditions,
the amount of HMGB1 and its respective oxidation state are confused by the fact
that HMGB1 is present in platelets and other white blood cells 37-42. As a result,
HMGB1 is secreted during the clotting process when serum is prepared, creating
a confounding artifactual HMGB1 presence in serum samples. Most of the > 1600
studies of circulating HMGB1 that were designed to assess the role of HMGB1 in
various clinical conditions have analyzed it in serum rather than plasma37.
Therefore, studies of serum HMGB1 provide little insight into whether HMGB1 is
involved in the particular disease state being studied let alone what proteoforms
are involve in that disease.

9

1a5. Extracellular Function of HMGB1
HMGB1 that is released into circulation acts as a DAMP and has a range of
cytokine, chemokine, metabolic and neuroimmune effects. The extracellular
effects of HMGB1 are mediated via binding to several receptors, including the
receptor for advanced glycation end products (RAGE), toll-like receptors (TLR’s)
and CXCR4 (Figure 1a3)43-46.

Figure 1a3. HMGB1 extracellular binding partners
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HMGB1 interaction with RAGE receptors has been shown to have two main
consequences: one, regulation of cell motility and neurite outgrowth via activation
of guanosine triphosphatases (GTPases) and two, NF-κB signaling pathway that
activates a cascade of proinflammatory cytokine release from human monocytes
and macrophages47,48. RAGE binding by HMGB1 therefore seems to play a role in
both HMGB1’s cytokine and chemokine extracellular effects. HMGB1 can also
interact with and activate both TLR2 and TLR4, which, like RAGE signaling, results
in NF-κB activation and increased transcription of inflammatory genes, ultimately
leading to the release of cytokines like TNF-α and Interleukin-8 (IL-8)49. HMGB1
can also form a complex with DNA fragments to bind to and activate TLR9, which
through RAGE interaction, modifies cytokine release 50. HMGB1 binding to CXCR4
has been shown to be necessary for the migration and maturation of dendritic
cells51.
The chemokine and cytokine effects of HMGB1 have been localized to the
A-box and B-box of HMGB1, respectively. The A-box of HMGB1 has been shown
to induce migration of immune cells at ten times lower concentrations than that of
the B-box, implicating it as the driver of HMGB1’s chemokine effects52. The A-box
of HMGB1 even has anti-inflammatory properties in certain contexts, for instance,
reducing biological indicators of severe acute pancreatitis in mouse models53. The
B-box of HMGB1 has been demonstrated to have opposing effects to the A-box,
significantly increasing inflammatory responses54. Any PTMs or binding partners
that selectively effect either HMG box therefore have the potential to enhance or
11

reduce the chemokine or cytokine effects of HMGB1, altering the immune
response to the protein.
1a6. Relationship Between HMGB1 Oxidation State and Function
The regulation of HMGB1 binding affinity and selectivity to its extracellular binding
partners is not well understood but has been previously proposed to be a function
of oxidation state. In these previously proposed models, HMGB1 oxidation state
and extracellular function were linked in a trinary relationship (Figure 1a4). The
three cysteine residues in HMGB1 could be fully reduced, in a disulfide between
Cys-23 and Cys-45 with Cys-106 reduced and terminally oxidized to a cysteic acid
at all three cysteine residues. These three oxidative proteoforms were proposed
to correspond to chemokine functionality, cytokine functionality and inactivity,
respectively. Sequential release of each HMGB1 oxidative proteoform from injured
cells as pathological oxidative stress progressed therefore was proposed to
correspond to each stage of inflammation; specifically, leukocyte recruitment,
leukocyte activation and eventual resolution of inflammation (reviewed in Lu et.
al.)55. Much of the literature supporting such a relationship has been confused by
retractions, temporary removal, or expressions of concern and there is not a
definitive description of HMGB1 oxidative behavior remaining in the literature 56-64.
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Figure 1a4. Previously proposed model of HMGB1 oxidation-function relation

Probing of the literature regarding HMGB1 oxidation state and extracellular
function after flagged or retracted publications are disregarded presents a
confused, incomplete picture of how HMGB1 oxidation effects its function.
Supporting the previously proposed paradigm relating HMGB1 oxidation to
function, it was shown that under mild oxidizing conditions, disulfide bond
formation occurs between Cys-23 and Cys-45 but that Cys-106 remains in the
reduced form and that this regulates the function of HMGB1 in response to
oxidation65. Support for the previously accepted paradigm was also derived from
the finding that caspase-mediated oxidation of HMGB1 at Cys-106 induces
immunological tolerance in apoptotic cells; whereas, formation of the Cys-23/Cys45 disulfide does not affect the activity of HMGB1 in this setting66. Contrasting the
previously accepted paradigm, however, oxidation of all three Cys-residues was
found to improve TLR4 binding, cytokine release and immune responses 67. In
13

addition, oxidative stress elicited platelet/leukocyte inflammatory interactions
through oxidative modifications to the three Cys-residues in HMGB168.
Furthermore, LPS-induced kidney sepsis induced HMGB1 oxidation to the Cys23/Cys-45 disulfide, which correlated with the ability of HMGB1 to induce
inflammation7. Finally, terminal oxidation of Cys-106 in HMGB1 to a cysteic acid
was found to promote apoptosis and increase cell death upon exposure to
chemotherapeutic agents9. The existing literature definitively shows HMGB1
oxidation has functional consequences but when HMGB1 oxidation occurs and
exactly what those functional consequences are is currently ambiguous.
1b. Drug-Induced Liver Injury (DILI)
1b1. Clinical and Pharmaceutical Implications of DILI
Drug-induced liver injury (DILI) refers to any form of hepatotoxicity induced
by exogenous pharmacological agents. Metabolism of exogenous compounds
occurs largely in the liver and as such, it is one of the most common organs sites
for adverse drug reactions. DILI can occur as a direct chemical action of a drug
and its metabolites but can also occur indirectly through immune activation. In the
case of the latter, drugs or metabolites form covalent adducts with cellular proteins
that resemble an immunogen, which is then presented to the immune system
through MHC, ultimately setting off an inappropriate auto-immune response that
results in damage to the cells in which the adduct has formed (reviewed in Griem
et. al., 199869). Generally, such immune-mediated DILI is idiosyncratic, meaning it
occurs unpredictably as compared to direct chemical toxicity that occurs relatively
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uniformly across the population. It is difficult to quantify DILI but it is estimated to
occur in 2.7 to 19 individuals per 100,000 people per year (reviewed in Björnsson
et. al., 2020)70. DILI manifests as either hepatic necrosis, disruption of the biliary
ducts or both. The clinical and societal burden of DILI is high due to its severe
outcomes, which include acute liver failure requiring transplantation and death.
DILI also has a meaningful effect on the development of pharmaceuticals;
as the most common form of adverse drug reaction (ADR), DILI is the most
frequent reason for the removal of approved drugs from the market71.
Compounding the challenge to drug development posed by the frequency of DILI,
objective diagnosis of DILI is extremely difficult. There are no adequate predictive
or specific circulating markers of DILI and even biopsy is insufficient to
unambiguously diagnose DILI72. Clinicians rely on contextual information and
several poorly predictive indicators of liver function, including

alanine

transaminase (ALT), aspartate transaminase (AST) and bilirubin. The range of
normal values for these markers in wide and their levels can be affected by many
biological events unrelated to DILI. Missed diagnoses and misdiagnosis of DILI is
therefore common, making it difficult to detect and accurately quantify the rate of
DILI a drug will cause in the population prior to approval 72. Better DILI biomarkers,
improved understanding of the molecular mechanisms of DILI and elucidation of
the regulation of immune response to DILI are all necessary to lower the clinical
and pharmaceutical burden of DILI.
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1b2. APAP Overdose as a DILI Model
The most common cause of DILI among the general population is overdose
of acetaminophen (APAP), which leads to over 30,000 hospitalizations and
hundreds of deaths per year73. APAP overdose is a good model of DILI not only
due to the frequency with which APAP overdose occurs but also because of its
molecular mechanisms. APAP overdose involves a direct, chemical insult to
hepatocytes and is therefore non-idiosyncratic (Figure 1b1). Most APAP (~90%)
is metabolized via glucuronidation and sulfation, while a small percentage is
metabolized via cytochrome P450 (CYP) enzymes to a reactive metabolite Nacetyl-p-quinoneimine (NAPQI). At therapeutic doses, NAPQI is detoxified via
intracellular glutathione stores. At toxic doses of about 4 g APAP per day in the
average healthy adult, intracellular glutathione stores are depleted, and NAPQI is
able to covalently bind intracellular proteins, leading to mitochondrial dysfunction,
increase in reactive oxygen species (ROS) and free radicals, ultimately inducing
oncotic necrosis of hepatocytes74.
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Figure 1b1. Metabolism of APAP and mechanism of DILI

APAP overdose involves a consistent, dose-dependent direct chemical insult that
results in the necrotic release of intracellular proteins following acute oxidative
stress. As a result, DILI biomarker discovery, particularly discovery of oxidative
biomarkers, is likely to be much easier with APAP overdose than other forms of
DILI.

1c. Liquid Chromatography Mass Spectrometry Proteomics
1c1. Principles of Chromatographic Separation of Peptides
Chromatography separates molecules of interest based on differential
partitioning between a stationary phase and mobile phase. In the case of
proteomics, peptides are separated based on their differential interaction between
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a column and a solvent. The amino acid composition of a peptide determines its
size, charge and hydrophobicity, which determine its affinity for the mobile phase
solvent compared to the column, and thus its degree of retention. Chromatography
adds a time component to analysis of a complex mixture, imparting each analyte
with a retention time that reflects its physical properties. Liquid chromatography
can be optimized for analytes of interest by altering the stationary or mobile phase
composition as well as the mobile phase flow rate or volume. A LC separation can
be “normal phase”, in which the column is more polar than the solvent, or “reverse
phase”, in which the solvent is more polar than the column. Separation of peptides
generally involves reverse phase chromatography, wherein peptides adsorb to the
surface of silica column and are eluted with a gradient of increasing organic solvent
concentration. Decreasing the flow rate and volume of a chromatographic
separation provides greater signal for a given amount of sample due to reduced
dilution in the mobile phase; flow rates on the scale of hundreds of nanoliters per
minute were used for work within this thesis75.
Liquid chromatographic separation can be further described by the Van
Deemter equation, shown in Table 1c1, which describes the separation power of
a column. Specifically, the Van Deemter equation describes the theoretical plate
height for a given column, determined by eddy diffusion, molecular diffusion and
mass transfer coefficient76. The parameters described by Van Deemter can all be
adjusted for ideal separation of analytes of interest.
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Van Deemter Equation: 𝐻 = 2𝜆𝐷𝑝 +
Which simplifies to: 𝑯 = 𝑨 +

𝑩
𝒖

2𝜆𝐷𝑚
𝑢

+

𝜔(𝑑𝑝 𝑜𝑟 𝑑𝑚)2 𝑢
𝐷𝑚

+

𝑅𝑑 2 𝑓 𝑢
𝐷𝑠

+ 𝑪𝒖

Term

Parameter

Factors

A

Eddy-diffusion

2𝜆𝐷𝑝

B

Longitudinal diffusion

2𝜆𝐷𝑚
𝑢

C

Resistance to mass transfer

𝜔(𝑑𝑝 𝑜𝑟 𝑑𝑚 )2 𝑢 𝑅𝑑 2𝑓 𝑢
+
𝐷𝑚
𝐷𝑠

u

Mobile phase velocity

Table 1c1. Van Deemter equation (adapted77)
H = plate height, λ = particle shape, Dp = particle diameter, Dm = mobile phase
diffusion coefficient, dc = capillary diameter, df = film thickness, Ds = diffusion
coefficient of stationary phase

Plate height is inversely proportional to peak width, therefore optimization for the
minimal possible plate height will result in narrow peaks and maximal separation
between analyte peaks. Eddy diffusion can be minimized with uniform column
packing that minimizes channels for differential flow. Molecular diffusion can be
minimized with greater flow rates that limit time on column for such diffusion to
occur. Resistance to mass transfer between the mobile and stationary phase can
be minimized by optimizing the composition of the two phases or lowering flow
rates. Optimization of a nano-flow chromatographic system is generally sufficient
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to impart a unique retention time on peptide analytes of interest; however, retention
time alone is insufficient to unambiguously identify peptide analytes, nor provide
information about PTMs to specific amino acids. A LC system was therefore
coupled to a mass spectrometer for the purposes of the work detailed in this thesis.
1c2. Principles of High-Resolution Mass Spectrometry
The analysis of eluent from a LC system by MS provides additional
information about analytes, specifically their mass to charge ratio (m/z) and signal
intensity. Mass spectrometers can only analyze charged molecules so the m/z for
a given analyte is dependent on both the mass and number of charges the analyte
gains during the process of ionization. Signal intensity is not an inherently
quantitative measure; intensity depends not only mols of analyte present but also
its ionization efficiency and ion suppression effects from its matrix78. MS-based
methods for absolute quantitation are described in subsequent sections.
Eluent from a chromatographic system must be ionized before it can be
analyzed via MS. Ionization occurs in the ion source, of which there are several
varieties, including

matrix-assisted, laser desorption

ionization

(MALDI),

electrospray ionization (ESI), chemical ionization (CI) and others. Ionization source
is selected based on the chromatographic system and analyte properties. Peptides
and other biomolecules are relatively fragile with a predisposition to fragment
during ionization. Biomolecules are therefore most commonly ionized gently via
ESI, which ionizes liquid droplets under atmospheric pressure and minimizes
analyte fragmentation79. ESI involves the application of a high voltage at the end
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of a capillary that converts the eluent liquid into charged droplets. Solvent
evaporation decreases the liquid volume and increases the charge density of a
droplet until it splits into charged ions in the gas phase (Figure 1c1).
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Figure 1c1. Electrospray ionization mechanism (adapted78)

MALDI is also considered a “soft” ionization method suitable for biomolecules but
requires analytes be embedded in a solid matrix and is not suitable for interfacing
with LC systems such as ESI. Also unlike MALDI, ESI produces analyte ions of
multiple charge states, allowing analysis of high molecular weight analytes by
increasing the denominator in the m/z of analytes too heavy for analysis with a
single charge m/z. ESI can produce both positive and negative charge ions but
negative ion ESI is much more difficult due to negative ion instability in typical
chromatography solvents, tendency for corona discharge and electrical arching,
among other issues80.
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After analytes have been ionized in the ion source of a mass spectrometer,
the resulting ions are separated based on m/z by a mass analyzer, of which there
are several different types. The unique engineering of different mass analyzers
imparts different mass resolving power, accuracy and range of analyzable ion
masses. Mass resolving power refers to how similarly the masses of two ions can
be and still be adequately differentiated. It is technically defined as m/z divided by
the peak width necessary for separation at m/z81. The orbitrap mass analyzer is a
high-resolution analyzer that provides sufficient resolution and accuracy to
differentiate up to 0.001 Da differences in mass82. An orbitrap analyzer traps ions
in an elliptical orbit around an electrode by balancing electrostatic attraction and
inertia83. An LTQ-Orbitrap XL high-resolution instrument was used for work in this
thesis. An orbitrap can uniquely act as not only a mass analyzer but also as a
detector, which converts ions into a digital signal. Trapped oscillating ions in an
orbitrap induce an oscillating charge in detector electrodes that can be converted
from time domain signals to frequency domain signals (mass spectra) by Fourier
transformation83.
Additional information from MS-analysis can be gained using tandem mass
spectrometry (MS/MS). MS/MS analysis incorporates a second mass analyzer and
collision step that allows for precursor ions to be selected, fragmented into product
ions and then analyzed to reveal structural information about the precursor ion. In
proteomics mass spectrometry, MS/MS allows peptide ions to be selected and
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fragmented into a collection of peptide fragments that when reconstructed, provide
mass information about each amino acid in the peptide (Figure 1c2).
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Figure 1c2. Peptide MS/MS analysis example

An orbitrap mass analyzer can be used in MS/MS experiments either as a second
mass analyzer and detector separated from the first mass analyzer in space or as
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both mass analyzers, where MS steps are separated in time. Fragmentation of
precursor ions can be achieved through multiple mechanisms, including collisioninduced dissociation (CID), electron capture dissociation (ECD), photodissociation
and others. Dissociation methods differ in energy and speed of dissociation
causing them to induce different fragmentation patterns and differ in usefulness
depending on type of analyte. In this work, an orbitrap mass analyzer was
preceded by a quadrupole mass filter and CID cell for fragmentation separated in
space (Figure 1c3).

HCD Collision Cell

Quadrupole

Transfer Multipole

Bent Flatapole

C-Trap

Injection Flatapole
S-lens
Capillary

Orbitrap Mass Analyzer
Source

Figure 1c3. Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer
schematic with internal parts labeled and ion path shown in red.

There are four major scans or experiment types that are used in tandem mass
spectrometry: product ion scan, precursor ion scan, neutral loss scan and selected
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reaction monitoring (SRM) (Figure 1c4). A product ion scan selects a specific ion
in the first mass analyzer and scans for all fragments in the second mass analyzer.
In a precursor ion scan, a specific fragment is selected for in the second mass
analyzer and all precursor ions that produce said fragment are scanned for in the
first mass analyzer. A neutral loss scan monitors loss of specific functional groups
during fragmentation by scanning for all precursor and corresponding product ions
that lose a specific m/z. SRM involves selection of specific precursor and product
ions. Multiple reaction monitoring (MRM) and parallel reaction monitoring (PRM)
are forms of SRM in which multiple specific product ions are rapidly scanned for
and all product ions are scanned for, respectively. Time separated MS/MS is
capable of product ions scans but not precursor or neutral loss scanning.
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Figure 1c4. Types of MS/MS scans
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CHAPTER 2: Characterization of APAP Overdose and HMGB1 Release
2a. Introduction
Drug-induced liver injury (DILI) is a serious clinical problem but research
into its molecular mechanisms and potential biomarkers is challenged by the
difficulty of fully recapitulating liver biochemistry in vitro. Most hepatocarcinoma
cell lines have differential expression of key metabolic enzymes compared to
endogenous hepatocytes, resulting in differences in DILI in vitro compared to in
vivo. Specifically, most hepatocarcinoma cell lines lack full expression of Phase I
metabolic enzymes such as CYPs, changing the metabolic fate of a range of
exogenous compounds. Cultured primary human hepatocytes retain most of their
in vivo characteristics but are difficult to use given their scarcity and inherent
variability between donors. HepaRG hepatocarcinoma cells provide most of the
features of primary hepatocytes with the stable phenotype and lack of senescence
characteristic of hepatocarcinoma cell lines. Specifically, HepaRG cells maintain
their metabolic conjugation capacity, plasma protein production ability and
expression of key metabolic enzymes such as CYPs84,85. As such, HepaRG cells
provide an excellent model to study DILI in vitro.
Overdose of acetaminophen (APAP) is both one of the most common
causes of DILI and one of the hepatotoxins most frequently used to study DILI. At
overdose concentrations, APAP, induces mitochondrial dysfunction, acute
oxidative stress and ultimately oncotic necrosis of hepatocytes. APAP is
metabolized in the liver primarily by sulfation and glucuronidation, which account
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for roughly 30% and 50% of APAP

metabolism, respectively 86. The

sulfotransferase enzymes SULT1A1 and SULT1A3 and SULT1C4 are responsible
for

transferring

a

sulphonate

group

from

3′-phosphoadenosine-5′-

phosphosulphate (PAPS) to the hydroxyl group of APAP to produce
acetaminophen-sulfate (APAP-S)87. The UDP- glucuronosyltransferases UGT1A1,
UGT1A6 and UGT1A9, among others, have been shown to catalyze the transfer
of a glucuronosyl group from UDP-glucuronic acid to the hydroxyl group of APAP
to produce acetaminophen-glucuronide (APAP-G)88. APAP sulfation is a saturable
pathway at therapeutic doses while glucuronidation is non-saturable and as such,
APAP is shunted from the sulfation pathway to the glucuronidation pathway at
overdose concentrations86. A minority of APAP (~10%) is metabolized to reactive
metabolite N-acetyl-p-quinoneimine (NAPQI) primarily mediated by CYP2E1, and
CYP3A4 and potentially others89,90. NAPQI is thought to be responsible for the
toxic effects of APAP overdose via covalent binding to mitochondrial proteins that
ultimately induces oncotic necrosis of hepatocytes74.
HMGB1 is an intracellular protein that has been shown to have a role in the
immune system’s response to tissue damage, such as hepatic necrosis following
APAP overdose91. The mechanism of HMGB1 release, effects of its release and
modification state of released HMGB1 are all not fully understood in the context
APAP overdose. HMGB1 has been previously shown to be released during APAP
overdose, both in vivo and in HepaRG cell models91,92. The biological relevance of
such HMGB1 release, however, is confused by the lack of consensus in the
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literature about HMGB1 release in other types of cell death. In the case of apoptotic
cell death, there are conflicting reports of HMGB1 release, which may be
dependent on cell type and HMGB1 sub-cellular localization8,36. Additionally,
release of HMGB1 in other contexts has been proposed to be an active process
dependent on PTMs15,16,31. The characterization of the HepaRG-APAP model of
DILI and subsequent release of HMGB1 are described here, with a focus on
validating the model for study of HMGB1 oxidative proteoforms present following
APAP overdose.

2b. Results
2b1. Characterization of HepaRG Cells and Their Response to APAP
The hepatocarcinoma HepaRG cell line was used as an in vitro model of
the hepatic environment for this thesis due to the unique similarities of HepaRG
cells to primary human hepatocytes. HepaRG cells recapitulated liver morphology
better than other hepatocarcinoma cell lines are able to by differentiating into
hepatic-like and biliary-like cells that form bile cuniculi-like structures (Figure 2b1).
Morphological recapitulation of the in vivo hepatic environment preserves the
interactions between different hepatic cell types that may alter the outcome of DILI.
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Figure 2b1. HepaRG cells under brightfield light microscopy. Hepatocyte-like
(CYP450 expressing) cells differentiate into small granular clusters, biliary
epithelial-like cells differentiate into clearer, flat cells separating the hepatic-like
clusters.

HepaRG cells were also used to recapitulate the metabolic functions of the liver,
specifically the metabolism of exogenous compound APAP. In vivo, the majority of
APAP is conjugated into APAP-S and APAP-G for excretion in the urine. While the
sulfation metabolic pathway for APAP becomes saturated at therapeutic doses,
APAP glucuronidation is considered non-saturable in vivo86. Measurement of
APAP-S and APAP-G production in HepaRG cells exposed to variable APAP
concentrations for 24-hours shows a similar pattern, with elevated APAP-G
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production and saturated APAP-S production (Figure 2b3). At millimolar
concentrations of APAP, the majority of APAP is shunted from the sulfation
pathway to the glucuronidation pathway, indicating saturation of the former.
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Figure 2b2. APAP sulfation (APAP-S) and glucuronidation (APAP-G) metabolite
concentrations following 24-hour incubation with varying APAP concentration.

HepaRG cells, like primary hepatocytes, produce the reactive APAP metabolite
NAPQI and demonstrate the resulting toxicity observed in vivo. Peak serum APAP
concentrations of roughly 2.0 mM or above in vivo is associated development of
hepatoxicity93. HepaRG cells show a similar dose-toxicity profile, with significant
changes in cell viability after a 24-hour exposure demonstrated at 3.0 mM and
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above but not at 1.0 mM, relative to control media exposure (Figure 2b2). At 10
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Figure 2b3. HepaRG cell viability after 24-hour exposure to variable [APAP].

Hepatocytes killed by APAP overdose undergo oncotic necrosis and not apoptosis
or other regulated forms of cell death. Cell staining with agents specific for necrosis
and apoptosis show that HepaRG cells overdosed with APAP undergo minimal
apoptosis and substantial necrosis as compared to HepaRG cells exposed to
known apoptotic agent doxorubicin (Dox), which induces significant apoptosis
followed by secondary necrosis (Figure 2b4). Secondary necrosis in vivo is
generally pre-empted by phagocytosis of apoptotic cell bodies.
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= propidium iodide stain (Necrosis)

= pSIVA stain (Apoptosis)

Figure 2b4. Cell-death specific staining of HepaRG cells following 24-hour
exposure to 10 mM APAP or 100 M doxorubicin (Dox). Green polarity sensitive
indicator of apoptosis (pSIVA) stain stains apoptotic cells, red propidium iodide (PI)
stains primary or secondary necrotic cells. Doxorubicin is a known apoptotic agent
at 100 M concentration.
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2b2. Characterization of HMGB1 Release During DILI
Significant levels of oncotic necrosis create the opportunity for unregulated
release of intracellular proteins in various oxidation and modification states.
Abundant intracellular protein HMGB1 is released in a dose-dependent fashion
from APAP-overdosed HepaRG cells (Figure 2b5). Relatively substantial release
of HMGB1 observed at 5.0 and 10.0 mM APAP correlate with cell death in greater
than 75% of cells, suggesting release by passive diffusion following loss of
membrane integrity.

MW
kDa

Acetaminophen (mM)

0.0 1.0 2.0 3.0 5.0 10.0

50 ng
HMGB1

Figure 2b5. Anti-HMGB1 western blot of APAP-exposed HepaRG media (24hours).

In HepaRG cells, apoptosis induced by doxorubicin induces substantial release of
HMGB1 (Figure 2b5). Over a 24-hour exposure period, HMGB1 is lost from the
cytosolic fraction of HepaRG cells and accumulates in the extracellular media, with
some HMGB1 retained in the nuclear fraction. HMGB1 release into the media
occurs at later time points of apoptosis and correlates with loss of HMGB1 from
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the cytosol, potentially indicating passive release of HMGB1 following loss of
membrane integrity during secondary necrosis. HepaRG cells demonstrated
significant HMGB1 localization to the cytosol, as shown by negative control cells.
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Figure 2b5. Anti-HMGB1 time course western blot of nuclear, cytosolic and media
fraction of HepaRG cells exposed to 100 M Dox compared to control.

Release of HMGB1 by HepaRG cells during DILI and other contexts can be
accurately measured via two-dimensional nano-ultra-high- performance liquid
chromatography parallel reaction monitoring/high-resolution mass spectrometry
(2D-nano-UHPLC-PRM/HRMS). After a 24-hour exposure to 10 mM APAP, the
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majority of HepaRG HMGB1 is released into the media, with only 24% of HMGB1
remaining in cell lysate (Figure 2b6).

Figure 2b6. HMGB1 in media and lysate of HepaRG cells after 24-hour, 10mM
APAP exposure as determined by 2D-nano-UHPLC-PRM/HRMS.

HMGB1 release during APAP-overdose is significant not only in terms of
percentage of HMGB1 released, but also in comparison to the amount of HMGB1
released in other contexts. HMBG1 is released by activated immune cells in vivo;
a THP-1 phorbol 12-myristate 13-acetate (PMA) stimulated model of activated
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immune cells shows comparatively less HMGB1 release to APAP-overdosed cells
(Figure 2b7). Control HepaRG cells and THP-1 cells similarly release less HMGB1
than APAP-overdosed HepaRG cells. The unregulated release of HMGB1 during
APAP-overdose creates the potential for oxidative or otherwise modified
proteoforms of HMGB1 to reach circulation in vivo and alter the immune response
to liver injury.

Figure 2b7. HMGB1 in media of control and APAP-exposed HepaRG cells, control
cells and LPS-stimulated macrophages. APAP-overdosed cells were exposed to
10 mM APAP for 24 hours, PMA-differentiated THP-1 cells were exposed to 100
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ng/mL LPS for 24 hours. HMGB1 was measured by 2D-nano-UHPLCPRM/HRMS.

2c. Discussion
HepaRG cells recapitulate both the morphology and biochemistry of the in
vivo liver better than other hepatocarcinoma cell lines while avoiding the
phenotypic heterogeneity and scarcity of primary human hepatocytes. Work
detailed here demonstrates that HepaRG cells produced a similar set of APAP
metabolites and APAP toxicity profile compared to published reports of APAP
overdose in vivo93. Specifically, HepaRG cells produced both major APAP
metabolites, APAP-S and APAP-G, with production of APAP-S being substantially
less than that of APAP-G due to saturation of the sulfation pathway like occurs in
vivo. Inorganic sulfur needed to produce sulfation co-factor PAPS is much less
abundant than glucuronidation cofactor UDP-glucuronic acid, which results in
exhaustion of sulfation but not glucuronidation capacity at and above therapeutic
APAP doses94. APAP-S therefore goes from being approximately 30% of
metabolized APAP to substantially less at millimolar doses, as observed in this
HepaRG model86. APAP-G production does not seem to increase linearly with
dose at 5.0 mM and 10.0 mM APAP, likely due to the extensive cell death observed
at these doses.
HMGB1 release during cell death is still controversial, with contrasting
evidence about the mechanisms involved during different types of cell death.
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HMGB1 has been shown to be passively released during oncotic necrosis,
including APAP overdose-induced necrosis91,92. HMGB1 was released from
APAP-overdosed HepaRG cells in significant quantities, further confirming the
applicability of this cell model for study of DILI and the role of HMGB1. The release
of HMGB1 during apoptosis is less clear, as reports of both significant HMGB1
release and no HMGB1 release have been published in the literature 8,36. One
theory as to why HMGB1 release during apoptosis is inconsistent, is that HMGB1
sub-cellular localization is different in distinct cell types, leading to differential
release. DNA-binding by HMGB1 during apoptosis has been shown to prevent
HMGB1 release HMGB1 sub-cellular localization to the nucleus and cytosol might
prevent and allow release, respectively21. HepaRG cells showed significant
HMGB1 localization to the cytosol and significant HMGB1 release following
apoptosis, further supporting the role of sub-cellular localization in release.
HMGB1 release during apoptosis occurred at later time points where
secondary necrosis was observed via cell staining. Secondary necrosis involves
the loss of membrane integrity so release during apoptosis is likely passive and
unregulated, similar to release during oncotic necrosis. Oncotic necrosis, like that
observed during APAP overdose, involves acute oxidative stress that is absent
during apoptosis or in stimulated immune cells actively secreting HMGB1. Three
cysteine residues in HMGB1 impart a sensitivity to oxidation such that HMGB1
released from an oxidative environment is likely to have oxidative modifications
that differentiate it from HMGB1 released from a reducing environment. Similar
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passive release mechanisms during apoptosis and necrosis therefore could still
result in the release of different HMGB1 proteoforms that bind different
extracellular receptors and help to explain the differential immune response to
either type of tissue injury. HepaRG cells are demonstrated here to be an ideal
model system to study the HMGB1 proteoforms released during APAP overdose
and the potential implications.

2d. Materials and Methods
2d1. Chemicals and Reagents
The following chemicals and regents were obtained from the listed vendors.
Reagents and solvents were LC-MS-grade quality unless otherwise noted. Burdick
and Jackson (Muskegon, MI): LC-MS grade water and acetonitrile. Cambridge
Isotope Laboratories (Andover, MA): [13C615N2] lysine, [13C915N1] tyrosine, [13C1]
acetaminophen and [2H6] acetic anhydride. EMSCO/FISHER (Philadelphia, PA):
pierce Protein A/G magnetic agarose beads, formic acid, Gibco HepaRG
cryopreserved cells, Gibco HepaRG thaw, plate and general-purpose medium
supplement, Gibco Williams E medium with glutaMAX, ATCC THP-1 cells and
RPMI 1640 media. Fisher Scientific (Pittsburgh, PA): ammonium hydroxide
(Optima). MilliporeSigma (Billerica, MA): anti-HMGB1 rabbit pAb (H9539),
acetaminophen, ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor
cocktail, paracetamol. sulfate potassium salt (APAP-S) and paracetamol β-Dglucuronide (APAP-G). Novus Biologicals (Centennial, CO): polarity sensitive
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indicator of viability and propidium iodide. Promega (Madison, WI): mass spec
grade trypsin endo-proteinase. Thermo Fisher Scientific (Waltham, MA): tris(2carboxyethyl)-phosphine (TCEP), endo-proteinase Glu-C from Staphylococcus
aureus V8, Tris HCl pH 8 solution and dimethyl pimelimidate.
2d2. APAP Overdose Model Cell Culture
Differentiated HepaRG cells (EMSCO/Fisher, Philadelphia, PA) were seeded at a
density of 0.5x106 cells per well in 24 well plates in Williams E medium with
glutaMAX and 1x Gibco HepaRG thaw, plate and general-purpose medium
supplement added. Cells were cultured at 37 °C with 21% O2 and 5% CO2 for 8
days to allow full expression of cytochrome P450 enzymes, according to
manufacturer

instructions

(Biopredic

International,

Rennes,

France).

Acetaminophen exposure experiments were done with variable acetaminophen in
Williams E medium added to cells for up to 24 hours.
2d2. Activated Immune Cell Model Cell Culture
THP-1 (EMSCO/Fisher, Philadelphia, PA) cells were grown to confluence in RPMI1640 media supplemented with 10% FBS, 100,000 units/L penicillin, 100 mg/L
streptomycin and 0.05 mM β-mercaptoethanol (BME). THP-1 cells were
differentiated into macrophages via a 48-hour exposure to 100 nM phorbol 12myristate 13-acetate (PMA) in RPMI-1640 media, after which they were cultured
in previously described RPMI media for 24-hours. Macrophages were activated
with a 24-hour exposure to 100 ng/mL lipopolysaccharide (LPS), after which media
was collected for HMGB1 quantitation via high-resolution mass spectrometry.
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2d3. Anti-HMGB1 Western Blots
HMGB1 in media and cell lysate was detected via an HMGB1 pAb (H9539,
MilliporeSigma) and anti-rabbit horseradish peroxidase (HRP) (Santa Cruz
Biotechnology, Dallas, TX). Cell lysate was collected and lysed via pulse
sonication in RIPA buffer containing 1x protease inhibitor cocktail. Cell
fractionation was done as follows: cells were centrifugated at 3000 x g for 5 min
and resuspended in 100 L hypotonic solution (50 mM MgCl 2, 10 mM NaCl, 20
mM Tris-HCl, pH 7.4) on ice and incubated for 15 min. A 5 L aliquot of 10%
IGEPAL CA-630 detergent was added to samples and vortexed. The supernatant
of samples centrifuged at 3000 x g at 4 °C for 10 min was taken as the cytoplasmic
fraction, while the remaining pellet was resuspended in 100 L NP-40 lysis buffer,
pulse sonicated and centrifuged at 14,000 x g at 4 °C for 30 min; the resulting
supernatant was taken as the nuclear fraction. Variable volumes of media dried
under nitrogen gas and cell fractions were suspended in NuPAGE LDS sample
buffer (1×) containing 2% β-mercaptoethanol (BME). Samples were loaded into 412% polyacrylamide gradient gel and run in MOPS buffer in reducing conditions
for 75 minutes at 150V. Proteins were transferred onto a nitrocellulose membrane
with 45V for 65 minutes on ice. After blocking with 5% BSA in PBST, primary
antibody was incubated overnight in blocking buffer at a 1:3000 concentration.
Western blots were visualized by use of electrochemical luminescence (ECL)
reagents and a digital developer (GE Healthcare).
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2d4. Cell Staining and Microscopy
Necrosis-specific and apoptosis-specific staining were done with polarity sensitive
indicator of viability (pSIVA) and propidium iodide (PI) dyes (Novus Biologicals),
respectively. Live cells were washed with PBS and stained in PBS with 20 L/mL
pSIVA or 10 L/mL PI for 10 minutes before imaging. Stained and unstained cells
were imaged with a BioTek Cytation 5 imager (Agilent Technologies) at 10x
magnification in brightfield and either red or green fluorescence filter for PI and
pSIVA, respectively. Green fluorescence: 488 nm excitation and 530 nm emission,
red fluorescence: 535 nm excitation and 617 nm emission. HepaRG cells were
image after 24-hour exposure to 10 mM APAP as well as after a 24-hour exposure
to 100 M doxorubicin, both in Williams E media. Cell viability was measured via
0.4% trypan blue staining (Fisher Scientific) and cell counting.
2d5. Mass Spectrometry APAP Metabolite Quantitation
Media from HepaRG cells exposed to variable APAP concentrations in Williams E
media for 24 hours was collected for analysis on a Thermo Triple Stage
Quadrupole (TSQ Quantum) mass spectrometer (Thermo Scientific) with an APCI
source operated in positive ion mode coupled to an Agilent 1100 Series HPLC
system (Waters Corp., Milford, MA, USA). A Kinetex column (C18, 2.1 × 30 mm,
2.6 μm particle size; Phenomenex, Torrance, CA) was used for separation on
HPLC system. Samples were loaded into the LC system via a 5 L injection and
metabolites were separated via linear gradient at a flow rate of 0.3 mL/min. Mobile
phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid
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in ACN/water (80:20). The gradient conditions were as follows: 2% B at 0 min, 2%
B at 2.5 min, 8% B at 2.51 min, 8% B at 4.5 min, and 70% B at 4.51 min, 100% B
at 11 min, 100% B at 15 min, 2% B at 15.5 min, followed by an 8.5 min equilibration
period. Operating conditions for the TSQ Quantum were: vaporizer temperature at
450°C; heated capillary temperature at 250 °C with the corona discharge needle
set at 30 µA; nitrogen as sheath (25 psi) and auxiliary (5 arbitrary units) gas. A
total of 50 ng 13C6 APAP internal standard was added to each sample, which were
precipitated with a methanol/water (80:20) mixture via centrifugation at 15,000 x g
for 10 min to remove residual protein. For absolute quantification, APAP-S and
APAP-G standard curves ranging from 3 g to 94 ng and 6 g to 375 ng,
respectively, were generated in the same matrix under identical conditions (Figure
1S1). Data analysis was performed using Xcalibur software (Thermo Scientific).
The PRM for peptides of interest was schedule as described in Table S1.
2d6. HMGB1 Immunopurification and In-Gel Preparation for LC-MS
Immunopurification and LC-MS preparation followed the protocol described in
detail in Weng et. al., 201832. Briefly, 100 g anti-HMGB1 rabbit pAb (H9539,
MilliporeSigma) was incubated with 10 mg of protein A/G beads at 4 °C overnight.
After removing the antibody solution, beads were washed with 1 mL of PBS 3 times
before being resuspended in 1 mL of PBS to a bead concentration of 10 mg/mL.
This suspension was used to immunopurify 20 media samples with 0.5 mg beads
added to each 400 L media sample. Each sample was spiked with 100 L IP lysis
buffer and 13 ng SILAC-HMGB1 internal standard before incubation overnight at
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4 °C. Post-incubation, beads were suspended in 20 μL of NuPAGE LDS sample
buffer (1×) containing 2% (BME) and heated to 95 °C for 10 min before being
loaded to 4-12% NuPAGE Bis-Tris polyacrylamide gel. The gel was run under 150
V for 75 minutes. Staining of the gel with colloidal Coomassie blue staining kit was
done at room temperature overnight. Gels were destained with deionized (DI)
water for 30−60 min and the gel region between 25 and 37 kDa containing HMGB1
was cut out. Gel pieces were acetylated with [2H6] acetic anhydride (d6-AA) after
dehydrating with acetonitrile (ACN) by mixing the gel pieces with 5 μL d6-AA and
10 μL 0.1 M aqueous NH4HCO3. After addition of 50 μL of 0.1 M aqueous
NH4HCO3, the pH of the mixture was adjusted to ∼8 (determined by pH paper)
with concentrated NH4OH. After incubation at 37 °C for 30−60 min, the supernatant
was removed, and the gel pieces were washed three times with water. After
washing, each sample had 2 μg of endoproteinase Glu-C in 50 mM ammonium
acetate, pH 4 added and were incubated overnight at 37 °C. Digestion supernatant
and sonication extracted gel supernatant were dried under nitrogen gas for LC-MS
analysis.
2d7. SILAC Internal Standard Production
SILAC internal standard was prepared and purified as described previously 32.
Briefly, the coding sequence of human HMGB1 was cloned into a pRK5 plasmid
and linked to the glutathione S-transferase (GST) tag and the plasmid was
expanded in Escherichia coli. Human kidney HEK293 cells (ATCC CRL-1573)
were transfected with GST−HMGB1 pRK5 plasmid using lipofectamine 2000
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transfection reagent (Invitrogen). Transfected HEK293 cells were cultured in
DMEM/F12/SILAC medium containing 0.2 mM [13C915N1] tyrosine and 0.5 mM
[13C615N2] lysine for at least three passages. Transfected cells were harvested in
NP-40 lysis buffer containing protease inhibitor cocktail after 24 h transfection.
Lysis via sonication followed by centrifugation to remove cellular debris yielded
SILAC-HMGB1-containing supernatant that was incubated with GSH Sepharose
beads at 4 °C overnight. Beads were washed and SILAC-HMGB1 was released
via TEV enzymatic cleavage overnight at 4 °C.
2d8. Mass Spectrometry HMGB1 Quantitation
Mass spectrometry was conducted on a Q Exactive HF hybrid quadrupole-Orbitrap
mass spectrometer coupled to a Dionex Ultimate 3000 RSLC nano with capillary
flowmeter chromatographic system (Thermo Fisher Scientific, San Jose, CA). A
trapping column (Acclaim PepMap C 18 cartridge 1 mm × 5 mm, 100 Å, Thermo
Scientific) and analytical column (C18 AQ nano-LC column with a 10 μm pulled tip
75 μm × 25 cm, 3 μm particle size; Columntip, New Haven, CT) were used in the
2D system for preconcentration and peptide separation, respectively. The 2Dnano-LC system was controlled by Xcalibur software from the Q-Exactive mass
spectrometer. Samples were loaded onto the trapping solvent with an 8 μL
injection and loading solvent of water/acetonitrile (99.7:0.3 v/v) containing 0.2%
formic acid. Peptides were separated on the analytical column with a linear
gradient at a flow rate of 0.4 μL/min: 2% B at 2 min, 5% B at 15 min, 35% B at 40
min, 99% B at 50−60 min, 2% B at 58−75 min. Solvent A was water/acetonitrile
46

(99.5:0.5 v/v) containing 0.1% formic acid, and solvent B was acetonitrile/water
(98:2 v/v) containing 0.1% formic acid. Nanospray Flex ion source (Thermo
Scientific) was used for ionization. Spectrometer analysis conditions were: spray
voltage 2500 V, ion transfer capillary temperature 250 °C, ion polarity positive, Slens RF level 53, in-source collision-induced dissociation (CID) 1.0 eV. The fullscan parameters were resolution 60 000, automatic gain control (AGC) target 1 ×
106, maximum IT 100 ms, scan range m/z 300−1600. The PRM parameters were
resolution 30 000, AGC target 5 × 105, maximum IT 80 ms, loop count 15, isolation
window 1.5 Da, NCE 25. The PRM for peptides of interest was schedule as
described in Table S1 and shown in their respective sequence positions in Figure
2b7.

Figure 2b7. HMGB1 sequence with Glu-C peptides used for absolute
quantitation underlined.
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CHAPTER 3: Quantification of HMGB1 Oxidation State in DILI
3a. Introduction
HMGB1 is a damage-associated molecular pattern (DAMP) that when
released from cells can induce a range of immune responses, including
inflammation, migration of maturing dendritic cells and release of cytokines like
TNFα8,51,95. The diversity of immune responses to HMGB1 is underscored by its
ability to bind and activate a range of extracellular receptors, which include RAGE,
CXCL 12, TLR2 and TLR4, among others43-46. HMGB1 extracellular receptor
affinity and the resulting immune response could be altered by HMGB1 PTMs that
effect the protein’s structure. Since PTM’s are dependent on the intracellular
environment from which HMGB1 is released, specifically modified versions or
“proteoforms” of HMGB1 could act as indicators of specific intracellular events. For
example, it has been previously proposed that an overdose of APAP results in the
release of certain oxidized HMGB1 proteoforms that tailor the immune response
to the overdose96. Specifically, it was proposed that HMGB1 oxidation state and
extracellular function were linked in a trinary relationship in which HMGB1 cysteine
residues were either fully reduced, in a disulfide between Cys-23 and Cys-45 with
Cys-106 reduced, or terminally oxidized at all three cysteine residues 96. These
oxidation states were proposed to correspond to chemokine functionality, cytokine
functionality and inactivity, respectively.
The release of specific HMGB1 oxidative proteoforms that control a specific
program of immune response during APAP overdose is an attractive idea but an
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open question in the literature; the aforementioned theory of HMGB1 oxidation is,
in fact, largely unsupported. The literature describing the oxidative behavior of
HMGB1 is confused by retractions, temporary removal, or expressions of concern
following reports of data fabrication in a key lab56-64. As such, there is no definitive,
evidenced-based description of HMGB1 oxidative behavior in a pathological
condition involving acute oxidative stress. Determining which HMGB1 proteoforms
are present following APAP overdose is, however, motivated by more than just
epistemological considerations. There are no sufficiently predictive or specific
biomarkers for DILI and diagnosis is generally made by elimination of other
causes, resulting in frequent missed and misdiagnosis. Oxidative proteoforms of
HMGB1 specifically generated in pathological conditions have the potential to act
as DILI or other pathological state-specific biomarkers. Additionally, the
contribution of HMGB1 to immune-mediated pathology is such that neutralizing
anti-HMGB1 antibodies significantly decrease the lethality of injuries like
acetaminophen-overdose8. Insight into the mechanisms of HMGB1-mediated
immune response may lead to the development of new treatments or therapeutics
for APAP overdose and other conditions.
Here, I report the characterization of HMGB1 oxidation state in an in vitro
hepatocarcinoma cell model of APAP overdose using two-dimensional nano-ultrahigh-performance liquid chromatography parallel reaction monitoring/highresolution mass spectrometry (2D-nano-UHPLC-PRM/HRMS). Covalent labeling
of free cysteine thiols with acrylamide with or without preceding cysteine reduction
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allowed for differentiation between free thiols and disulfide cysteine residues in
HMGB1. A [13C15N]-HMGB1 internal standard, prepared through stable isotope
labeling by amino acids in cell culture (SILAC) was used for normalization and
quantification. HMGB1 digestion with trypsin or Glu-C (Staph. aureus V8)
endoproteinases yielded peptides containing all three HMGB1 cysteine residues,
allowing direct detection of thiol cysteine CAE-derivative, disulfide cysteine and
terminally oxidized cysteic acid residue. I demonstrate four distinct oxidative
HMGB1 proteoforms released from APAP-overdose cells, a selectivity for disulfide
formation between Cys-23 and Cys-45, and the ability of Cys-106 to readily form
disulfides with thiols on other molecules.

3b. Results
Relative, unbiased quantification of cysteine residue oxidation state
required the development of an entirely novel 2D-Nano-UHPLC-PRM/MS
experimental procedure. APAP-overdosed HepaRG cell media samples were
aliquoted into two parts, differentially reduced and reacted with acrylamide to
convert all free thiol cysteine residues into 2-propanamide (carbamidoethyl, CAE)
cysteine, after which HMGB1 immunoprecipitation and LC-high resolution mass
spectrometry (HRMS) analysis was used to analyze HMGB1 cysteine oxidation
state (Figure 3b1).
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Figure 3b1. HMGB1 cysteine purification and labeling protocol

In a data dependent (DDA) LC/MS analysis of both recombinant and biologicalorigin HMGB1, only three cysteine oxidation states were detected: free thiol,
disulfide and a terminally oxidized cysteic acid residue. Quantitation was therefore
limited to these three oxidative modifications. Covalent modification of free thiols
with acrylamide was used to prevent artifactual oxidation while variable TCEP
reduction allowed for quantitation of total cysteine and free thiol cysteine, therefore
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allowing for the calculation of disulfide cysteine. Acrylamide labeled cysteinecontaining peptides were detected for each cysteine residue and were normalized
with corresponding internal standard peptides, of which representative
chromatograms for each are shown in Figure 3b2. Endogenous terminal oxidation
was only observed at Cys-106 and not Cys-23 or Cys-45, with terminally oxidized
internal standard peaks demonstrating the detectability of those absent peptides.
(Figure 3b3). Typical mass spectra for each peptide of interest are displayed in
Figure S3-S7.
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Acrylamide Peptides
M[O]SSYAFFVQTC[CAE]RE

NS: 1.91 E4
509.5637 to 971.4767
M[O]SSY*AFFVQTC[CAE]RE

Relative Intensity (%)

NS: 2.17 E4
512.9061 to 971.4767
RPPSAFFLFC[CAE]SEYRPK

NS: 1.65 E4
672.6769 to 953.4509
RPPSAFFLFC[CAE]SEY*RPK*

NS: 1.68 E4
678.6907 to 971.4924
FSKKC[CAE]SE

NS: 6.30 E4
495.2476 to 235.092
FSK*K*C[CAE]SE

NS: 2.08 E5
503.2618 to 235.092

Figure 3b2. Typical 2D-Nano-UHPLC-PRM/MS chromatograms of propenamide
(CAE) labeled HMGB1 peptides. K* = [13C615N2] lysine, Y* = [13C915N1].
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Terminally Oxidized Peptides
M[O]SSYAFFVQTC[O3H]RE

NS: 0

501.8796 to 801.3560
M[O]SSY*AFFVQTC[O3H]RE

Relative Intensity (%)

NS: 1.60 E4
505.2220 to 801.3560
RPPSAFFLFC[O3H]SEYRPK

NS: 3.79 E3
664.9927 to 244.1656
RPPSAFFLFC[O3H]SEY*RPK*

NS: 6.76 E3
671.0065 to 252.1798
FSKKC[O3H]SE

NS: 0
483.7214 to 819.3671
FSK*K*C[O3H]SE

NS: 5.48 E3
491.7356 to 835.3955

Figure 3b3. Typical 2D-Nano-UHPLC-PRM/MS chromatograms of cysteic acid
(O3H) HMGB1 peptides. K* = [13C615N2] lysine, Y* = [13C915N1].

Accurate quantitation of terminally oxidized peptides relative to reduced or disulfide
peptides required determination of the difference in ionization efficiency between
cysteic acid-containing peptides and CAE-derivatives. 2D-Nano-UHPLC-PRM/MS
analysis of known amounts of synthetic peptides of the same amino acid
sequence, differing only in cysteine state (cysteic acid or CAE-derivative) showed
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that terminally oxidized HMGB1 peptides ionize 5.1 times poorer than
propenamide-labeled peptides (Table 3b1). Differences in ionization efficiency
were adjusted for when making relative quantitative comparisons between
terminally oxidized and thiol or disulfide oxidation states.

Table 3b1. Ionization efficiency of cysteic acid (O3H) and CAE-derivatized
synthetic peptides as determined by 2D-Nano-UHPLC-PRM/MS

Peptide

Peak Area/Mol Ionization Efficiency
on Column
Normalization Factor

MSSYAFFVQTC[O3H]R 8 ± 3 E+19
MSSYAFFVQTC[CAE]R 40 ± 7 E+19

5.1
1.0

Relative HMGB1 redox state quantitation showed that Cys-23 and Cys-45 had
matching oxidation state, within error. Cys-23 was 82% disulfide and 18% free thiol
(Figure 3b4). Cys-45 was 87% disulfide and 13% free thiol (Figure 3b5). Cys-106
differed from the other two HMGB1 cysteine residues both in presence of terminal
oxidation and relative amount of disulfide formation; 46% of Cys-106 was disulfide,
42% free thiol and 12% terminally oxidized. (Figure 3b6). Biological and
instrumental variation between different sets of samples was minimal, as
evidenced by the less than 10% variation in Cys-23 oxidation quantitation between
three sets of samples, each with n=5 (Figure 3b7). Each sample set produced the
same percent thiol and disulfide at Cys-23, within error.
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Cys-23 Proteoform Relative Abundance

Percent Proteoform (%)

100
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Figure 3b4. Cys-23 oxidation state relative quantitation (n=5)
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Cys-45 Proteoform Relative Abundance

Percent Proteoform (%)
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20

0
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Figure 3b5. Cys-45 oxidation state relative quantitation (n=4)
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Proteoform
Figure 3b6. Cys-106 oxidation state relative quantitation (n=5)
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Cys-23 Replicate Comparison
Percent Proteoform (%)
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19.0

20

0
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Proteoform
Figure 3b7. Variation in Cys-23 oxidation quantification between three sample
sets of biological replicates

3c. Discussion
HMGB1 is passively released in large amounts during acute oxidative
pathology like (APAP) overdose and has an important role in the subsequent
immune response. Despite the potential for oxidative proteoforms to serve as
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pathology-specific biomarkers and their relevance for the biological response to
pathology, there is not a consensus on what HMGB1 oxidative proteoforms are
present following APAP overdose. The data shown here demonstrated that at least
four discreet oxidative proteoforms were present extracellularly following APAP
overdose and allowed quantification of their relative abundance. All three HMGB1
cysteine residues are at least 18% free thiol, demonstrating that the fully reduced
form of HMGB1 accounts for approximately 18% of released HMGB1 (Figure 3c1A). Given the close structural proximity and identical rates of disulfide formation,
Cys-23 and Cys-45 are presumed to exclusively form a disulfide with one another
and as such, the remaining 82% of released HMGB1 is presumed to have a Cys23 to Cys-45 disulfide with variation at Cys-106. There is free thiol Cys-106
unaccounted for by the 18% fully reduced HMGB1 so as follows mathematically,
24% released HMGB1 is reduced at Cys-106 with a disulfide at Cys-23 and Cys45 (Figure 3c1-B). To account for the Cys-106 terminal oxidation, 12% of released
HMGB1 must have a disulfide between Cys-23 and Cys-45 with Cys-106 terminally
oxidized to a cysteic acid residue (Figure 3c1-C). Around 45% of Cys-106 in
released HMGB1 is left unaccounted for by the previous three proteoforms and all
45% of remaining Cys-106 is in the disulfide oxidation state. Since Cys-23 and
Cys-45 are fully accounted for and unavailable for disulfide formation with Cys106, the remaining proteoform must involve an intermolecular disulfide with
another intracellular thiol (Figure 3c1-D)
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Figure 3c1. HMGB1 proteoforms present following APAP overdose

Both Cys-23 and Cys-45 are in the A-box region of HMGB1, which has been
shown to be critical for the chemokine extracellular function of the protein52. The
majority of HMGB1 released during APAP overdose has a disulfide between these
two residues; while the degree of structural change imparted by this disulfide is
unclear, it has the potential to significantly alter receptor binding affinity and the
chemokine response to HMGB1. Cys-106 is within the B-Box region of HMGB1,
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which has been shown to be primarily responsible for the cytokine activities of
HMGB154. The effect of terminal oxidation or disulfide formation within this region
is unknown but again, potentially provides a mechanism by which extracellular
function could be altered. The formation of an intermolecular disulfide at Cys-106
creates the possibility of complexation that could allow non-canonical extracellular
receptor binding previously unreported with monomer HMGB1. Binding of HMGB1
to the CXCR4, for instance, is known to be mediated via non-covalent interaction
with CXCL 1245. Similar covalent complexes with novel binding targets may
provide an entirely new explanation for HMGB1 extracellular functional diversity.

3d. Materials and Methods
APAP-overdosed HepaRG cell media was split into two samples, each
spiked with tris(2-carboxyethyl)phosphine (TCEP) reduced stable isotope labeling
by amino acids in cell culture (SILAC) HMGB1 internal standard. Variable TCEP
reduction

followed

by

acrylamide

labeling

was

followed

by

aHMGB1

immunoprecipitation and UHPLC-HRMS analysis of trypsin peptides.
Peptides containing Cys-23 and Cys-106 were obtained via trypsin digest while a
peptide containing Cys-45 was obtained via Glu-C digest. Lysine residues in GluC peptides were acetylated with acetic anhydride to improve chromatographic
behavior
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3d1. Chemicals and Reagents
Reagents and solvents were LC-MS-grade quality unless otherwise noted.
Biosynth Carbosynth (previously Vivitide) (Gardner, MA) provided peptides with
the

sequences

M[O]SSYAFFVQTC[O3H]RE,

M[O]SSYAFFVQTCRE,

RPPSAFFLFCSEYRPK and RPPSAFFLFC[O3H]SEYRPK (>95%). Burdick and
Jackson (Muskegon, MI) supplied LC-MS grade water and acetonitrile. Cambridge
Isotope Laboratories (Andover, MA): [13C615N2] lysine, [13C915N1] tyrosine and [2H6]
acetic anhydride. EMSCO/FISHER (Philadelphia, PA) supplied Pierce Protein A/G
magnetic agarose beads, formic acid, Dulbecco’s phosphate buffered saline
(DPBS), Gibco HepaRG cryopreserved cells, Gibco HepaRG thaw, plate and
general-purpose medium supplement, and Gibco Williams E medium with
glutaMAX. Fisher Scientific (Pittsburgh, PA) supplied ammonium hydroxide
(Optima). MilliporeSigma (Billerica, MA) suppled the anti-HMGB1 rabbit polyclonal
antibody (pAb) (H9539), APAP, acrylamide, ethylenediaminetetraacetic acid
(EDTA)-free

protease

inhibitor

cocktail,

L-cysteine,

triethanolamine

and

ethanolamine. Promega (Madison, WI) supplied mass spectrometry grade trypsin
endo-proteinase. Thermo Fisher Scientific (Waltham, MA) supplied tris(2carboxyethyl)-phosphine (TCEP), endoproteinase Glu-C from Staphylococcus
aureus V8, Tris HCl pH 8 solution, and dimethyl pimelimidate (DMP).
3d2. APAP Hepatocyte Overdose Cell Model
Differentiated HepaRG cells were seeded at a density of 0.5x10 6 cells per well in
24 well plates in Williams E medium with glutaMAX and 1x Gibco HepaRG thaw,
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plate and general-purpose medium supplement added. Cells were cultured at 37
°C with 21% O2 and 5% CO2 for 8 days to allow full expression of cytochrome P450
enzymes, according to manufacturer instructions (Biopredic International, Rennes,
France). Williams E medium containing 10 mM APAP was added to cells for 24-h
to model toxic overdose of APAP. Media and released cell proteins were collected
following APAP exposure to high concentrations of APAP.
3d3. Expression and Purification of SILAC-Labeled HMGB1
SILAC HMGB1 internal standard was prepared and purified as described
previously32. Briefly, the coding sequence of human HMGB1 was cloned into a
pRK5 plasmid and linked to the glutathione S-transferase (GST) tag and the
plasmid was expanded in Escherichia coli. Human kidney HEK293 cells (ATCC
CRL-1573) were transfected with GST−HMGB1 pRK5 plasmid using lipofectamine
2000 transfection reagent (Invitrogen). Transfected HEK293 cells were cultured in
DMEM/F12/SILAC medium containing 0.2 mM [13C915N1] tyrosine and 0.5 mM
[13C615N2] lysine for at least three passages. Transfected cells were harvested in
NP-40 lysis buffer containing protease inhibitor cocktail after 24 h transfection.
Lysis via sonication followed by centrifugation to remove cellular debris yielded
SILAC-HMGB1-containing supernatant that was incubated with GSH Sepharose
beads at 4 °C overnight. Beads were washed and SILAC-HMGB1 was released
via TEV enzymatic cleavage overnight at 4 °C.
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3d4. HMGB1 Cys-CAE Derivatization
Media from APAP (10 mM, 24-h exposure) or control HepaRG cell samples was
split into two aliquots and an identical amount of reduced SILAC HMGB1 internal
standard (100 ng) was spiked into each. One aliquot for each sample was reduced
via addition of TCEP to a final concentration of 50 mM and 30-min incubation at
37 °C. A concentrated solution of acrylamide in Tris HCl, pH 8.0 was added to
reduced and non-reduced aliquots to yield a final concentration of 0.5 M
acrylamide and 30 mM Tris. After acrylamide addition, samples were incubated at
room temperature in the dark for 1-h. An equimolar Cys quench to remove residual
acrylamide was done following acrylamide derivatization by incubation for 30-min
at room temperature.
3d5. HMGB1 IP
Protein A/G magnetic beads were washed twice with DPBS and twice with buffer
A (0.1 M sodium phosphate, pH 7.4) before use. A total of 40 μL dispersed, prewashed beads was incubated with 100 μL buffer A and 100 μL Anti-HMGB1 rabbit
pAb for 2-h at 4 °C, followed by addition of 400 μL buffer A and overnight incubation
at 4 °C. Beads were then washed twice with buffer A and twice with 1 mL of crosslinking buffer (0.2 M triethanolamine, pH 8). Beads were suspended in 1 mL of 25
mM DMP prepared in cross-linking buffer and incubated at room temperature for
1-h. Beads were washed once with 1 mL blocking buffer (0.1 M ethanolamine, pH
8.2) and incubated at room temperature for 30-min in 1 mL blocking buffer.
Blocking buffer was then removed and beads were washed twice with PBS,
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followed by a 10-min incubation in elution buffer (0.1 M glycine-HCl, pH 2.5) at
room temperature and an additional two washed with PBS. Beads were aliquoted
into 10 clean protein LoBind tubes and control or APAP-overdosed cell media
acrylamide labeled as described previously was added for overnight incubation.
HMGB1 was eluted with 15-min vigorous shaking of beads in 100 μL elution buffer,
which was subsequently neutralized via addition of 50 uL 250 mM NH 4HCO3. Postelution, beads were washed once with 10 mM NH 4HCO3, pH 6.0 with wash solution
added to neutralization buffer to collect any residual HMGB1 still bound. Combined
elute was dried under N2 for subsequent resuspension and digestion.
3d6. In-Solution Lysine Acetylation and Enzymatic Digest
Samples digested with Glu-C were first acetylated with [2H6] acetic anhydride (AA)
as follows. Dried samples were resuspended in a solution containing 50 μL of
acetonitrile, 100 μL of 100 mM NH4HCO3 and 5 μL of AA pH adjusted to pH 8.0
via dropwise addition of ammonium hydroxide. Samples were incubated at 37 °C
for 1-h. Glu-C samples were then adjusted to pH 4 via dropwise addition of acetic
acid and 500 ng of Glu-C was added per sample. Samples digested with trypsin
were not acetylated and were directly resuspended in 100 μL of 25 mM NH 4HCO3
containing 40 ng of trypsin. Both digests were incubated overnight at 37 °C and
dried under N2 the following day. Samples were stored dry at -80 °C until LC-MS
analysis, at which point they were resuspended in 30 uL water/acetonitrile
(99.5:0.5 v/v) containing 0.1% formic acid.
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3d7. 2D-Nano-UHPLC-PRM/HR Mass Spectrometry
UHPLC-HRMS was conducted on a Q Exactive HF hybrid quadrupole-Orbitrap
mass spectrometer coupled to a Dionex Ultimate 3000 RSLC nano with capillary
flowmeter chromatographic system (Thermo Fisher Scientific, San Jose, CA). A
trapping column (Acclaim PepMap C 18 cartridge 1 mm × 5 mm, 100 Å, Thermo
Scientific) and analytical column (C18 AQ nano-LC column with a 10 μm pulled tip
75 μm × 25 cm, 3 μm particle size; Columntip, New Haven, CT) were used in the
2D system for preconcentration and peptide separation, respectively. The 2Dnano-LC system was controlled by Xcalibur software from the Q-Exactive mass
spectrometer. Samples were loaded onto the trapping solvent with an 8 μL
injection and loading solvent of water/acetonitrile (99.7:0.3 v/v) containing 0.2%
formic acid. Peptides were separated on the analytical column with a linear
gradient at a flow rate of 0.4 μL/min: 2% B at 2-min, 5% B at 15-min, 35% B at 40min, 99% B at 50- to 60-min, 2% B at 58−75 min. Solvent A was water/acetonitrile
(99.5:0.5 v/v) containing 0.1% formic acid, and solvent B was acetonitrile/water
(98:2 v/v) containing 0.1% formic acid. Nanospray Flex ion source (Thermo
Scientific) was used for ionization. Spectrometer analysis conditions were: spray
voltage 2500 V, ion transfer capillary temperature 250 °C, ion polarity positive, Slens RF level 53, in-source collision-induced dissociation (CID) 1.0 eV. The fullscan parameters were resolution 60 000, automatic gain control (AGC) target 1 ×
106, maximum IT 100 ms, scan range m/z 300−1600. The PRM parameters were
resolution 30 000, AGC target 5 × 105, maximum IT 80 ms, loop count 15, isolation
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window 1.5 Da, NCE 25. The PRM for peptides of interest was schedule as
described in Table S2 and S3.
3d8. HMGB1 Cys Oxidation State Quantification
Relative percent disulfide and thiol oxidation state at each HMGB1 Cys residue
was calculated using the acrylamide labeled signal in TCEP reduced and nonreduced samples. The four most intense transitions for each acrylamide peptide
were selected and the peak area ratio of unlabeled to SILAC- labeled peptide was
calculated for each in Skyline (MacCoss Laboratory, University of Washington,
Seattle, WA). The average area of the 4 transitions for each peptide in nonreduced samples was calculated as the signal representing free thiol Cys residues.
The same calculation for TCEP-reduced samples was used as the signal for free
thiol and disulfide Cys. Subtraction of the two yielded the signal for disulfide Cys
residues, allowing relative quantitation. Sulfonic acid oxidized Cys peptides were
also quantified with the peak area ratio of the four most intense transitions. Sulfonic
acid peptide signal intensity was adjusted for ionization efficiency differences
compared to a CAE-derivatized peptides by multiplying cysteic acid-containing
peptide area ratios by a factor of 5.1 based on analysis of the difference in peak
area per mol of the corresponding synthetic peptides analyzed by 2D-NanoUHPLC-PRM/HRMS. Relative quantitation of the three oxidation states was then
performed directly. Statistical analysis was performed with GraphPad Prism (v9.3,
GraphPad Software Inc., La Jolla, CA).
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CHAPTER 4: Disulfide Connectivity Determination
4a. Introduction
Several analytical techniques can be used to deduce protein disulfide
connectivity, including nuclear magnetic resonance spectroscopy (NMR), x-ray
crystallography and mass spectrometry (MS)97-99. MS is commonly used to
determine disulfide connectivity as it requires lower sample concentration and
purity compared to NMR or crystallography. While indirect, quantitative MS-based
methods, similar to those described in Chapter 3, have previously been used to
elucidate disulfide connectivity in the literature, the gold standard for MS- disulfide
connectivity analysis requires direct detection of intact disulfide bonds 100. Direct
detection of disulfide connectivity via LC-MS is challenged by the related
phenomena of thiol-disulfide exchange and disulfide scrambling, which result in
disulfide bonds swapping connectivity with either a free thiol or another disulfide
bond, respectively (Figure 4a1). Disulfide exchange and scrambling are known
phenomena that depend primarily on the proximity of cysteine residues, solution
pH, concentration of free thiols and solution temperature101. Maintenance of
solution pH below pH 7.0 and elimination of any excess free thiols in solution is
generally sufficient to avoid disulfide exchange and scrambling at or below 37
C102.
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A. Thiol-disulfide Exchange:

R SH

S

S
S

R S
SH

B. Disulfide Scrambling :
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S S

S S
S S

Figure 4a1.

Schematic of (A) thiol-disulfide exchange and (B) disulfide

scrambling.

If sample preparation avoids introduction of artifactual disulfides,
endogenously occurring disulfide can be directly detected via intact disulfide
peptides. Enzymatic digestion of disulfide-containing proteins must, however, be
optimized to produce disulfide peptides with physical properties amenable to LCMS analysis; peptide length, mass and polarity, among other properties, can all
interfere with LC-MS detection. Optimized enzymatic digestion under non-reducing
conditions yields intact disulfide peptides that can be separated via 2D-nano70

UHPLC and then detected via PRM/HRMS. Fragmentation of parent disulfide
peptides via collision-induced dissociation, as was used here, typically results in
fragmentation of the peptide backbone and not the disulfide bond, producing
product ion spectra such as that shown in Figure 4a2. Matches in relative disulfide
abundance can therefore be confirmed as indications of disulfide connectivity via
direct detection of predicted disulfide linkages.

M[O]SSYAFFVQTCR
MS1++

M[O]SSYAFFVQTCR

CID Fragmentation
M[O]

*-b2

M[O]SSYAFFVQTCR
p-y2

CR
M[O]SSYAFFVQTCR

p-y6

FVQTCR
M[O]SSYAFFVQTCR

p-y8

AFFVQTCR
M[O]S

b3-*

M[O]SSYAFFVQTCR

p-y5

VQTCR
M[O]SSYAFFVQTCR

p-y10

SYAFFVQTCR

Figure 4b2. Example disulfide peptide chromatogram. Ion labels represent the
disulfide bridge as a dash with the peptide fragment on either side labeled as
normal (p = all amino acids on respective side, * = no amino acids).
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HMGB1 oxidation state has been previously proposed as a mechanism that
allows for tunable functional diversity when HMGB1 is released extracellularly 17.
HMGB1 oxidized proteoforms may therefore be uniquely important for dictating the
immune response following acute oxidative pathology like APAP overdose and
could potentially act as biomarkers of acute oxidative pathology. Relative
quantitation of HMGB1 cysteine oxidation state described in Chapter 3 provided
evidence for the release of 4 discreet HMGB1 proteoforms following APAP toxicity
with disulfide linkages between Cys-23 and Cys-45, as well as between Cys-106
and other intracellular thiols (Figure 4a3). Herein, a protein isolation and digestion
protocol were developed to yield detectable HMGB1 disulfide peptides for the
predicted disulfide connectivity and those peptides were searched for samples
containing biological HMGB1 from APAP-injured hepatocytes. We confirmed via
direct detection of disulfide peptides that Cys-23 and Cys-45 form a disulfide bridge
in vivo during APAP toxicity, and that Cys-106 forms an intermolecular disulfide
with unidentified intracellular thiols. Glutathionylated and cysteinyl Cys-106
peptides were generated with recombinant HMGB1 in vitro to demonstrate the
detectability of intermolecular disulfides at Cys-106, although neither was detected
in APAP-injured samples. Intermolecular Cys-106 to Cys-106 HMGB1 disulfide
formation was also investigated in vitro but such a disulfide peptide was not
detectable due to the physical properties of the residues surrounding Cys-106.
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Figure 4a3. Proposed HMGB1 disulfide linkages following APAP toxicity

4b. Results
4b1. Detection of HMGB1 disulfide peptides
Direct detection of HMGB1 disulfide peptides in biological samples first
required sample preparation protocols be optimized to avoid artifactual disulfide
formation, thiol-disulfide exchange, and disulfide scrambling. Thiol-disulfide
exchange and scrambling were observed at pH levels greater than pH 8.0 and
when millimolar concentrations of free thiol were present in solution with disulfides.
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Maintenance of solution pH at or below pH 8.0 and removal of cysteine quenching
steps was sufficient to avoid disulfide swapping or exchange, as demonstrated by
the preservation of disulfide peptides and absence of cysteinyl peptides in such
conditions (Figure 4b2). Such controls over thiol-disulfide exchange and disulfide
scrambling were used for the preparation of all samples.

B. No Cysteine Quench

A. Cysteine Quench

M[O]SSYAFFVQTCR

M[O]SSYAFFVQTCR

C

C

MS1++

MS1++
NS: 5.07 E5

NS: 0.0 E0

M[O]SSYAFFVQTCR
MS1+++

MS1+++
NS: 2.39 E6
M[O]SSYAFFVQTCR
M[O]SSYAFFVQTCR

p-y2
p-y6

Chloramine-T
Oxidation

M[O]SSYAFFVQTCR
M[O]SSYAFFVQTCR
+/- Cysteine
Quench, pH 8

NS: 6.60 E4
M[O]SSYAFFVQTCR
M[O]SSYAFFVQTCR

p-y2
NS: 1.42 E5

p-y6
NS: 7.00 E4

p-y8

p-y8

NS: 7.08 E4

b3-*

b3-*

NS: 7.21 E4

p-y5

LC/MS

p-y5
NS: 3.77 E4

p-y10

p-y10

NS: 3.06 E4

Figure 4b2. LC-MS detection of pH and thiol-dependent disulfide swapping.
Synthetic peptide M[O]SSYAFFQRTCR was oxidized with 0.5 mM chloramine-T
at either (A) pH 8.0 with 0.5 mM L-cysteine or (B) pH 7.0 with no added free thiol.
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Recombinant HMGB1 oxidized with chloramine-T was used to determine both
HMGB1 disulfide connectivity in vitro and the detectability of disulfide HMGB1
peptides via 2D-nano-UHPLC-PRM/HRMS. Recombinant HMGB1 oxidized with
chloramine-T and digested with trypsin yields a strong signal for a Cys-23 to Cys45 disulfide-linked peptide, further supporting disulfide formation between the two
residues, as well as indicating the detectability of such a peptide (Figure 4b3). No
peptides containing a disulfide between Cys-106 and any other HMGB1 residue
was detected in oxidized recombinant HMGB1. To test the formation of
intermolecular disulfides at Cys-106, recombinant HMGB1 was oxidized in the
presence of glutathione, the most abundant intracellular thiol. A tryptic peptide with
a Cys-106 to glutathione peptide was readily detected (Figure 4b4). Peptides
detected in recombinant, oxidized HMGB1 samples were monitored for in media
samples of APAP-injured HepaRG cells. The Cys-23 to Cys-45 disulfide peptide
was readily detected in biological samples (Figure 4b5). There was no evidence
of Cys-106 intermolecular disulfide formation with glutathione in biological
samples, nor was there evidence of disulfide formation between Cys-106 and
either Cys-23 or Cys-45. Representative mass spectra for each peptide are shown
in Figure S7-S9.
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M[O]SSYAFFVQTCR
CSER
y10-p
NS: 7.99 E5
973.9133 to 856.8796

y8-p
NS: 8.76 E5
973.9133 to 731.8319

y7-p
NS: 6.40 E5
973.9133 to 696.3134

y9-p
NS: 6.63 E5
973.9133 to 813.3636

b2-*
NS: 4.30 E5
973.9133 to 235.0747

y11-p
NS: 3.96 E5
973.9133 to 900.3956

NS: 3.40 E5
973.9133 to 622.7792

y5-p
NS: 1.25 E5
973.9133 to 549.2450

Figure 4b3. Chromatogram of Cys-23 to Cys-45 disulfide peptide. Recombinant
HMGB1 was oxidized with 0.5 mM chloramine-T in the presence of 0.5 mM
glutathione.
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RPPSAFFLFCSEYRPK
CEG
b8-*
NS: 1.23 E6
750.6872 to 916.5039

b7-*
NS: 1.17 E6
750.6872 to 803.4199

y6-*
NS: 9.18 E5
750.6872 to 779.4046

p-b2
NS: 7.97 E5
750.6872 to 725.6764

b6-*
NS: 5.79 E5
750.6872 to 656.3515

b9-*
NS: 5.85 E5
750.6872 to 1063.5724

y7-p
NS: 4.84 E5
750.6872 to 1187.4701

y4-*
NS: 4.84 E5
750.6872 to 563.3300

Figure 4b4. Chromatogram of Cys-106 to glutathione disulfide peptide.
Recombinant HMGB1 was oxidized with 0.5 mM chloramine-T in the presence of
0.5 mM glutathione.
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y10-p
NS: 1.94 E4
973.9133 to 856.8796

y8-p
NS: 1.51 E4
973.9133 to 731.8319

y7-p
NS: 9.94 E3
973.9133 to 696.3134

y9-p
NS: 1.33 E4
973.9133 to 813.3636

y2-*
NS: 9.47 E3
973.9133 to 235.0747

y11-p
y8-p

NS: 7.64 E3
973.9133 to 900.3956

y7-p

y6-p

NS: 5.16 E3
973.9133 to 622.7792

y7-p

y10-p
y9-p

y5-p
NS: 1.66 E3
973.9133 to 549.2450

Figure 4b5. Chromatogram and spectrum of Cys-23 to Cys-45 HMGB1 disulfide
peptide detected in APAP-injured cell media. HepaRG cells were exposed to 10
mM APAP for 24-hours prior to collection and LC-MS analysis.

4b2. Probing for Cys-106 disulfide-mediated HMGB1 dimerization
HMGB1 intermolecular disulfide formation at Cys-106 might be nonspecific,
in which case HMGB1 would be expected to form disulfides with the most
abundant intracellular free thiols, like glutathione. Alternatively, disulfide formation
could be selective; for example, HMGB1 may preferentially form an intermolecular
disulfide at Cys-106 with Cys-106 on another HMGB1 molecule. HMGB1 dimer
formation was detected in biological samples via western blot, indicating that while
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potentially artifactual in this context, endogenous dimer formation is theoretically
possible (Figure 4b6).

50 ng rHMGB1
+TCEP
(25 mM)

-TCEP

18 uL APAP HepaRG Media
Media
+BME

Ladder
(kD)

+TCEP
(75 mM)

+TCEP
(50 mM)

+TCEP +TCEP +TCEP
(25 mM) (10 mM) (5 mM)

+TCEP
(0 mM)

100

HMGB1
dimer

75

50

37

25

HMGB1
monomer

Figure 4b5. Anti-HMGB1 western blot of APAP-injured cell media samples
reduced with varying amounts of TCEP pre-gel.

Protein analysis via LC-MS is contingent on enzymatic digestion of proteins into
peptide fragments with properties amenable to LC-MS analysis, including length,
mass, polarity and homogeneity of cleavage. Several endoproteinases digestion
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enzymes and protocols were attempted to yield a Cys-106 disulfide-containing
peptide with adequate physical properties for LC-MS analysis. The cleavage
specificity of endoproteinase chymotrypsin theoretically yielded the most
reasonably sized Cys-106 peptide and was therefore chosen as the primary
enzyme for investigation of Cys-106 disulfides. Chymotrypsin digestion of
recombinant HMGB1 oxidized with chloramine-T yielded peptides N-terminal and
C-terminal to a 7 amino acid sequence containing Cys-106 but neither a free thiol
nor disulfide peptide containing Cys-106 could be detected (Figure 4b6). There
are several potential chymotrypsin cleavage sites within the Cys-106-containing
stretch of 7 amino acids that chymotrypsin cleaves to either side. As such, all
potential free thiol monomer peptides as well as disulfide dimer peptides were
searched for via LC-MS and none were detected in either oxidized or control
recombinant HMGB1 samples. The properties and LC-MS characteristics of a
predicted chymotrypsin Cys-106 peptide CSEY oxidized to a disulfide via
chloramine-T was investigated with a synthetically produced peptide. Even after
LC-MS optimization, poor signal intensity and poor fragmentation were observed
with relatively high concentrations of pure synthetic disulfide CSEY-CSEY,
indicating the challenge the peptide in more complex sample matrices at low
concentrations (Figure 4b7).
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MS1

MS1

NS: 4.14 E6

NS: 9.84 E6

y11

b8

NS: 1.50 E7

NS: 4.85 E6

y12

Relative Intensity (%)

Relative Intensity (%)

…F_KDPNAPKRPPSAF__FLFCSEY__RPKIKGEHPGL_S…

NS: 6.76 E6

y8
NS: 4.17 E6

b12
NS: 2.20 E6

y3
NS: 8.35 E5

y6
NS: 5.59 E5

b3
NS: 5.49 E5

y8

b4

NS: 1.63 E6

NS: 4.99 E5

y5

y7

NS: 1.29 E6

NS: 4.55 E5

y2

y7

NS: 1.35 E6

NS: 3.71 E5

Figure 4b6. Chromatograms of chymotrypsin HMGB1 peptides. Recombinant
HMGB1 oxidized with 0.5 mM chloramine-T digested with chymotrypsin yielded
detectable peptides flanking Cys-106 but the 7-amino acid peptide containing Cys106 was not detected as a free thiol or disulfide ( _ = chymotrypsin cleavage site).
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CSEY
CSEY
MS1+
NS: 2.11 E6

MS1++
NS: 4.19 E4

y2-*
NS: 9.88 E3

b2-p
NS: 5.71 E3

*-y3
NS: 3.55 E3

b1-p
NS: 0.0 E0

Figure 4b7. Chromatogram of 50 fmol synthetic Cys-106 peptide oxidized to a
disulfide with 0.5 mM chloramine-T.
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Peptide physical properties can negatively affect chromatographic or ionization
behavior during LC-MS but poor peptide detection can also be a function of
upstream issues, including poor protein digestion efficiency. The digestion
efficiency of chymotrypsin for HMGB1 was tested with a sequential trypsin and
chymotrypsin digest, in which the intensity of tryptic peptides before and after a
sequential chymotrypsin digest was compared (Figure 4b8). Chymotrypsin digest
of HMGB1 under conditions that minimize disulfide exchange is only 7% complete
at high-efficiency cleavage sites like phenylalanine residues (F) and 0.4%
complete at low-efficiency sites like leucine (L), assuming approximately equal
ionization efficiency of tryptic and chymotryptic peptides. Alternative enzymatic
digests did not yield any detectable Cys-106 disulfide peptides.
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HPDASVNF

b2

b5

NS: 1.59 E7

NS: 1.12 E6

b5

b2

NS: 1.49 E7

NS: 4.52 E5

y5
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Relative Intensity (%)
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NS: 1.35 E7

y6
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NS: 7.55 E6

NS: 2.97 E4
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NS: 8.20 E6

NS: 1.49 E4

7% cleavage at F
GEHPGL

y5

y3

NS: 1.59 E8

NS: 5.98 E5

y10
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NS: 9.46 E7

NS: 5.50 E5
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NS: 6.22 E7
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y4
NS: 1.45 E5
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NS: 3.58 E7

NS: 5.84 E4

y6

y5

NS: 3.42 E7

NS: 1.92 E4

b5

y3

NS: 1.38 E4

NS: 3.13 E7

0.4% cleavage at L
Figure 4b8. Chymotrypsin digest efficiency. Chromatograms of peptides produced
from tryptic digest (green) followed by chymotryptic digest (blue) of recombinant
HMGB1.
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4c. Discussion
HMGB1 is passively released during numerous pathological conditions,
including APAP overdose, in which released HMGB1 influences the immune
response to pathology91. It is well established that disulfide bonds can alter protein
properties, structure and function; as such, oxidative proteoforms of HMGB1 have
been previously proposed as a mechanism by which HMGB1 release during acute
pathology can be differentiated from HMGB1 in other contexts by the immune
system64,103. Quantitation of disulfide formation at each of HMGB1’s cysteine
residues described in Chapter 3 provided strong evidence for disulfide connectivity
between Cys-23 and Cys-45, as well as intermolecular disulfide formation between
Cys-106 and other intracellular thiols. Matching rates of disulfide formation at two
cysteine residues, while informative, is however potentially misleading and does
not definitively prove disulfide linkage. Disulfide connectivity is instead, best
demonstrated by direct detection of disulfide-linked peptides.
Using sample preparation protocols shown to minimize the confounding
effects of disulfide scrambling and artifactual disulfide formation, we directly
demonstrated the disulfide connectivity Cys-23 to Cys-106 in HMGB1 from a cell
model

of

APAP

overdose

via

the

Cys-23/Cys-45

peptide

[M(O)13SSYAFFVQTC23(C45SER47)R24], confirming quantitative data described in
Chapter 3. The Cys-23/Cys-45 disulfide bond potentially alters the structure of the
A box region of HMGB1, which contains both Cys-23 and Cys-45. The A box of
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HMGB1 has previously been implicated as the driver of HMGB1’s chemokine
effects as it has been shown to induce migration of immune cells at ten times lower
concentrations than that of the B box of HMGB152. Chloramine-T generates
hydroxyl radicals in solution, much like occurs during acute oxidative stress in
vivo104. The detection of the Cys-23/Cys-45 disulfide in recombinant HMGB1
oxidized with chloramine-T suggests this disulfide formation is a function of
proximity and can occur without the action of protein disulfide isomerase enzymes
or other binding partners. Previous models of HMGB1 oxidation posited that Cys23 to Cys-45 disulfide formation occurred during oxidative pathology but only in
one discreet proteoform where Cys-106 was fully reduced96. While this reduced
Cys-106 proteoform was observed, it was one of three proteoforms with a Cys-23
to Cys-45 disulfide, each varying in Cys-106 oxidation state.
Nearly 50% of Cys-106 in HMGB1 released from APAP-injured hepatocytes
was shown to be oxidized to a disulfide in Chapter 3; given that Cys-23 and Cys45 are disulfide-linked and were not shown to form a disulfide with Cys-106, any
disulfide formation at Cys-106 must be intermolecular. The formation of
intermolecular disulfides of HMGB1 by cross-linking Cys-106 to other intracellular
proteins, offers a potential explanation for the functional diversity of HMGB1 different protein disulfides could conceivably have different activities on the
relevant receptors activated by HMGB1.

Characterizing these cross-linked

HMGB1 disulfides poses a formidable challenge as no Cys-106 peptides disulfidelinked to GSH or Cys-106 on other HMGB1 molecules could be directly detected
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in APAP injured hepatocyte samples. GSH concentrations are relatively high in
hepatocytes so if Cys-106 intermolecular disulfide formation is indiscriminate, we
excepted robust GSH linking105. It is possible that GSH is one of many Cys-106
disulfide partners and that the resulting relatively low concentration of any one
disulfide prevents detection. Metabolic processing of HMGB1 intermolecular
disulfides, like to GSH, might produce unexpected modifications, for which we did
not look. Acetylation has previously been proposed as an HMGB1 regulatory PTM
and we cannot discount the possibility that one or more of the lysine residues close
to Cys-106 could have been acetylated, which would have prevented the
generation of a tryptic peptide containing Cys-10615. However, this seems very
unlikely as we were unable to detect any acetylated lysine residues when the Cys106-containing peptide was analyzed as a CAE derivative after Glu-C digestion.
HMGB1 Cys-106 disulfide formation may instead be specific to unidentified binding
partners that were not a part of our search.
One possible selective HMGB1 intermolecular disulfide partner is another
molecule of HMGB1, making Cys-106 disulfide formation a unique form of protein
self-aggregation. While a Cys-106 to GSH disulfide was generated and readily
detected in vitro, detection of a Cys-106 to Cys-106 intermolecular disulfide was
challenging in vitro due to the physical properties of the amino acids surrounding
Cys-106 and poor digestion efficiency of the sequence. Given our poor sensitivity
for a Cys-106 to Cys-106 intermolecular disulfide, we therefore cannot definitively
rule out its formation of during APAP toxicity. If Cys-106 inter-HMGB1 disulfides
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do occur endogenously, detection will either require derivatization of disulfide
peptides to improve the peptide’s physical properties or novel LC-MS techniques.
The stable isotope dilution UHPLC-HRMS method that has been developed for
HMGB1 Cys-106 disulfides can readily be adapted for plasma samples. This will
allow the importance of these disulfides to be assessed in APAP overdose as well
as in different inflammatory diseases while structural studies are conducted to fully
characterize the relevant cross-linked proteins.

Finally, we anticipate that

quantification of Cys-23/Cys-45 cross-linked HMGB1 in plasma will provide a more
specific biomarker of APAP overdose than the current method of analyzing all
HMGB1 proteoforms.106

4d. Materials and Methods
4d1. Chemicals and Reagents
Reagents and solvents were LC-MS-grade quality unless otherwise noted.
Biosynth Carbosynth (previously Vivitide) (Gardner, MA) provided peptides with
the sequences RPPSAFFLFCSEYRPK and CSEY (>95%) and recombinant
HMGB1 (PRO-581). Burdick and Jackson (Muskegon, MI) supplied LC-MS grade
water and acetonitrile. Cambridge Isotope Laboratories (Andover, MA): [13C615N2]
lysine, [13C915N1] tyrosine and [2H6] acetic anhydride. EMSCO/FISHER
(Philadelphia, PA) supplied Pierce Protein A/G magnetic agarose beads, formic
acid,

Dulbecco’s

phosphate

buffered

saline

(DPBS),

Gibco

HepaRG

cryopreserved cells, Gibco HepaRG thaw, plate and general-purpose medium
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supplement, and Gibco Williams E medium with glutaMAX. Fisher Scientific
(Pittsburgh, PA) supplied ammonium hydroxide (Optima). MilliporeSigma
(Billerica, MA) suppled the anti-HMGB1 rabbit polyclonal antibody (pAb) (H9539),
APAP, acrylamide and ethylenediaminetetraacetic acid (EDTA)-free protease
inhibitor cocktail, triethanolamine, ethanolamine and chloramine-T (trihydrate).
Promega (Madison, WI) supplied MS grade trypsin and chymotrypsin endoproteinase. Thermo Fisher Scientific (Waltham, MA) supplied tris(2-carboxyethyl)phosphine (TCEP), endoproteinase Glu-C from Staphylococcus aureus V8, Tris
HCl pH 8 solution, and dimethyl pimelimidate (DMP).
4d2. APAP Hepatocyte Overdose Model
Differentiated HepaRG cells were seeded at a density of 0.5x10 6 cells per well in
24 well plates in Williams E medium with glutaMAX and 1x Gibco HepaRG thaw,
plate and general-purpose medium supplement added. Cells were cultured at 37
°C with 21% O2 and 5% CO2 for 8 days to allow full expression of cytochrome P450
enzymes, according to manufacturer instructions (Biopredic International, Rennes,
France). Williams E medium containing 10 mM APAP was added to cells for 24-h
to model toxic overdose of APAP. Media and released cell proteins were collected
following APAP exposure to high concentrations of APAP.
4d3. Anti-HMGB1 Western Blot
HMGB1 in cell media was detected via an HMGB1 pAb (H9539, MilliporeSigma)
and anti-rabbit horseradish peroxidase (HRP) (Santa Cruz Biotechnology, Dallas,
TX). Variable volumes of media dried under nitrogen gas were suspended in
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NuPAGE LDS sample buffer (1×) containing 2% β-mercaptoethanol (BME) or
variable concentrations of tris(2-carboxyethyl)-phosphine (TCEP). Samples were
loaded into 4-12% polyacrylamide gradient gel and run in MOPS buffer in reducing
conditions for 75 minutes at 150V. Proteins were transferred onto a nitrocellulose
membrane with 45V for 65 minutes on ice. After blocking with 5% BSA in PBST,
primary antibody was incubated overnight in blocking buffer at a 1:3000
concentration. Western blots were visualized by use of electrochemical
luminescence (ECL) reagents and a digital developer (GE Healthcare).
4d4. Generation of Disulfide Peptides In Vitro
Recombinant HMGB1 or synthetic HMGB1 peptides were oxidized with 0.5 mM
chloramine-T in 30 mM Tris HCl pH 7.0 buffer for 1 hour at 37 C with or without
0.5 mM glutathione present for the generation of intermolecular disulfides.
Synthetic peptide samples were diluted in LC-MS running to concentrations in the
tens of fmol/L buffer and directly analyzed. Recombinant protein was
immunoprecipitated as described and digested with 60 ng trypsin overnight in 25
mM NH4HCO3 buffer, pH 7.0 at 37 C.
4d5. Isolation of Disulfide Peptides from APAP-Injured Samples
Protein A/G magnetic beads were washed twice with DPBS and twice with buffer
A (0.1 M sodium phosphate, pH 7.4) before use. A total of 40 μL dispersed, prewashed beads was incubated with 100 μL buffer A and 100 μL Anti-HMGB1 rabbit
pAb for 2-h at 4 °C, followed by addition of 400 μL buffer A and overnight incubation
at 4 °C. Beads were then washed twice with buffer A and twice with 1 mL of cross90

linking buffer (0.2 M triethanolamine, pH 8). Beads were suspended in 1 mL of 25
mM DMP prepared in cross-linking buffer and incubated at room temperature for
1-h. Beads were washed once with 1 mL blocking buffer (0.1 M ethanolamine, pH
8.2) and incubated at room temperature for 30-min in 1 mL blocking buffer.
Blocking buffer was then removed and beads were washed twice with PBS,
followed by a 10-min incubation in elution buffer (0.1 M glycine-HCl, pH 2.5) at
room temperature and an additional two washed with PBS. Beads were aliquoted
into 10 clean protein LoBind tubes and up to 500 uL of APAP-overdosed cell media
was added for overnight incubation. HMGB1 was eluted with 15-min vigorous
shaking of beads in 100 μL elution buffer, which was subsequently neutralized via
addition of 50 uL 250 mM NH4HCO3. Post-elution, beads were washed once with
10 mM NH4HCO3, pH 6.0 with wash solution added to neutralization buffer to
collect any residual HMGB1 still bound. Combined elute was dried under N 2 and
then resuspended in digestion buffer with either 40 ng of trypsin or 100 ng of
chymotrypsin, depending on the peptides of interest. Samples were digested
overnight, again dried under N2 gas and resuspended in running buffer for LC-MS
analysis.
4d6. 2D-Nano-UHPLC-PRM/HR Mass Spectrometry
UHPLC-HRMS was conducted on a Q Exactive HF hybrid quadrupole-Orbitrap
mass spectrometer coupled to a Dionex Ultimate 3000 RSLC nano with capillary
flowmeter chromatographic system (Thermo Fisher Scientific, San Jose, CA). A
trapping column (Acclaim PepMap C 18 cartridge 1 mm × 5 mm, 100 Å, Thermo
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Scientific) and analytical column (C18 AQ nano-LC column with a 10 μm pulled tip
75 μm × 25 cm, 3 μm particle size; Columntip, New Haven, CT) were used in the
2D system for preconcentration and peptide separation, respectively. The 2Dnano-LC system was controlled by Xcalibur software from the Q-Exactive mass
spectrometer. Samples were loaded onto the trapping solvent with an 8 μL
injection and loading solvent of water/acetonitrile (99.7:0.3 v/v) containing 0.2%
formic acid. Peptides were separated on the analytical column with a linear
gradient at a flow rate of 0.4 μL/min: 2% B at 2-min, 5% B at 15-min, 35% B at 40min, 99% B at 50- to 60-min, 2% B at 58−75 min. Solvent A was water/acetonitrile
(99.5:0.5 v/v) containing 0.1% formic acid, and solvent B was acetonitrile/water
(98:2 v/v) containing 0.1% formic acid. Nanospray Flex ion source (Thermo
Scientific) was used for ionization. Spectrometer analysis conditions were: spray
voltage 2500 V, ion transfer capillary temperature 250 °C, ion polarity positive, Slens RF level 53, in-source collision-induced dissociation (CID) 1.0 eV. The fullscan parameters were resolution 60 000, automatic gain control (AGC) target 1 ×
106, maximum IT 100 ms, scan range m/z 300−1600. The PRM parameters were
resolution 30 000, AGC target 5 × 105, maximum IT 80 ms, loop count 15, isolation
window 1.5 Da, NCE 25.

92

CHAPTER 5: Conclusions, Future Directions and Alternative Methods
5a. Conclusions on APAP Toxicity HMGB1 Proteoforms
HMGB1 is a multifunctional protein that acts both within cells and in the
extracellular environment following release 17. HMGB1 has many known
extracellular binding partners, and its release has been shown to induce different
immune responses depending on the context of release43-50. It is not, however, well
understood what drives selectivity for specific binding partners, nor how the
immune response to HMGB1 is tuned to the context of release. PTMs, particularly
oxidative modifications, have been implicated as a possible mechanism for
dictating HMGB1 extracellular binding and function 68. Models relating HMGB1
oxidation to function previously proposed three HMGB1 oxidative proteoforms that
were released during distinct phases of tissue damage and induced specific
immune responses: fully reduced HMGB1 was released at the onset of tissue
damaged and induced chemokine responses in immune cells, partially oxidized
HMGB1 with a disulfide between Cys-23 and Cys-45 was released during the peak
response to tissue damage, inducing cytokine response and HMGB1 fully oxidized
to a cysteic acid at each cysteine residue was released at the resolution of
inflammation and was functionally inactive 64. Literature retractions have not only
cast doubt on the relationship between oxidation state and function, but also called
into question what HMGB1 oxidative proteoforms are released during acute
oxidative pathology, if any at all56-64.
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Work described within this thesis definitively demonstrated the presence of
four oxidative proteoforms of HMGB1 released following APAP toxicity in a
hepatocyte cell model. Two oxidative proteoforms, fully reduced HMGB1 and Cys23 to Cys-45 disulfide with reduced Cys-106 HMGB1, have been proposed in
previous models of HMGB1 oxidation-function relationship. Two other oxidative
proteoforms, both with a Cys-23 to Cys-45 disulfide and either a cysteic acid at
Cys-106 or an intermolecular disulfide at Cys-106, have not been previously
proposed or described in the literature. We were unable to identify the partner or
partners for the intermolecular disulfide observed at Cys-106; the respective
proteoform therefore may actually represent a large number of distinct proteoforms
that differ in the disulfide binding partner. If a variety of HMGB1 complexes do form
via a Cys-106 intermolecular disulfide, the variety of immune response elicited by
HMGB1 might be explained by the differential extracellular receptor binding affinity
of each HMGB1-protein complex. Such a mechanism for HMGB1 extracellular
functional diversity has not previously been proposed. The novel oxidative
proteoforms described here account for over 60% of HMGB1 present after APAP
toxicity, indicating previously proposed models neglected to account for highly
abundant and potentially functionally critical oxidative proteoforms. Furthermore,
previous models proposed that HMGB1-driven inflammation was suppressed by
the release of an oxidative proteoform that was not observed in the work described
here, leaving the mechanism of inflammation resolution an open question.
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It remains to be seen what proteoforms of HMGB1 are released during
APAP toxicity in vivo or if a similar proteoform profile is observed in other acute
oxidative pathologies, like ischemia-reperfusion or myocardial infarction. Answers
to these questions will determine the utility of HMGB1 oxidative proteoforms as
biomarkers, whether for APAP toxicity, liver injury or acute oxidative pathology in
general. Both the presence of specific oxidative proteoforms and the relative
abundance may ultimately be informative biomarkers. The novel stable isotope
dilution UHPLC-HRMS method developed withing this thesis can be readily
adapted for plasma samples to determine HMGB1 oxidation status in vivo. Work
within this thesis determines which oxidative modifications are present and at what
relative abundance in a model of oxidative pathology but does not seek to describe
the functional implications of each oxidative modification. Work will need to be
done to either test the immune cell response to specific proteoforms, correlate the
presence of specific proteoforms will specific outcomes in vivo, or both.
Determination of the functional differences between proteoforms, if any, has the
potential to lead to the development of therapeutics. Neutralizing anti-HMGB1
antibodies have been shown to decrease the lethality of APAP-overdose;
antibodies against specific proteoforms may allow for fine-tuning of the immune
response to increase desired HMGB1-mediated immune processes and
decreased harmful effects8.
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5b. Future Directions
5b1. Determination of HMGB1 Intermolecular Disulfide Partner(s)
HMGB1 was unambiguously shown to form an intermolecular disulfide at
Cys-106 but the partner or partners that HMGB1 forms such disulfide was
undetermined. Intermolecular HMGB1 disulfide formation may be indiscriminate
and HMGB1 may form disulfides randomly with whatever free thiols are available
intracellularly. In this case, there are likely many disulfide binding partners, and an
untargeted approach will be needed to characterize the range of intermolecular
disulfides. Alternatively, HMGB1 could form intermolecular disulfides selectively.
Within the cell, HMGB1 is known to form non-covalent interactions with histone
proteins, Beclin1, p53 and several other proteins as a part of its diverse range of
functions107-109. HMGB1’s interactions with other intracellular proteins may bias its
intermolecular disulfide formation, causing HMGB1 to form disulfides only with
specific transcription factors or proteins involved in one of HMGB1’s intracellular
functions. Characterization of HMGB1’s intracellular protein interactions may yield
a short list of potential binding partners for which a targeted approach can be used
to confirm.
An untargeted LC-MS approach to HMGB1 intermolecular disulfide
characterization could be carried out by immunoprecipitating the HMGB1-protein
disulfide complexes and performing bottom-up shotgun proteomics on the complex
mix of peptides resulting from enzymatic digest of the HMGB1 complexes.
Immunopurification would need to be optimized to prevent reduction or scrambling
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of existing disulfides and introduction of artifactual disulfides by avoiding basic pH,
reducing agents, excess free thiol concentration and solution temperatures above
37 C. Various immunoprecipitation strategies could be employed to minimize
background noise, including multiple sequential purification steps, pre-purification
clearing with blank beads, or covalent antibody-bead linking to allow for washing
steps.

Pre-digestion

fractionation

of

HMGB1

complexes

through

gel

electrophoresis or chromatography could also be done to lower sample complexity
by splitting complexes among several samples. Bottom-up proteomics of the
resulting digested protein complexes differs from the targeted, top-down LC-MS
strategy employed within this thesis in that m/z signals detected in data dependent
acquisition (DDA) must be computationally deconvoluted into amino acid
sequences and then matched within databases of protein sequences. Greater
statistical rigor would be required to characterize false positive and negative
identifications, although targeted LC-MS or related methods could be used to
further confirm untargeted protein identification. If HMGB1 has many complexation
partners, much greater concentrations of HMGB1 than used here would be
required to detect any individual complex partner. Additionally, an untargeted
approach could fail to detect lower abundance complex partners or those that are
more difficult to detect via LC-MS.
A targeted approach to determining the binding partners of HMGB1 would
involve much of the same methodology outlined within this thesis. Methods
described here could easily be applied to other proteins hypothesized to form
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intermolecular disulfides with HMGB1, requiring only optimization of digestion
enzyme choice and conditions to ensure cleavage of amino acids around Cys-106
in HMGB1 and around all cysteine residues in the potential disulfide partner so
that any disulfide peptide between the two could be detected. Multiple enzymes
might be required in some cases. The rate limiting step for finding disulfide partners
via a targeted approach is the biological characterization of HMGB1’s intracellular
interactions. Much has been published on such interactions but deeper biological
insight into which are occur in what context will be required to reach an informed
hypothesis about potential disulfide partners. We have not ruled out the potential
for HMGB1-to-HMGB1 intermolecular disulfides at Cys-106; a targeted approach
could be used to further investigate the possibility but either derivatizations or
alternative digestion strategies would be required to generate a sufficiently
detectable disulfide peptide.
5b2. Characterization of HMGB1 Proteoform Extracellular Function
Work within this thesis describes the proteoforms of HMGB1 present
following APAP toxicity but does not seek to describe the functional properties of
each HMGB1 proteoform. Relatively pure stocks of a given proteoform will need
to be generated or purified, with the oxidation state of each stock confirmed by MS
or suitable alternative method before functional characterization can be performed.
Reagents such as chloramine-T and performic acid are known to selectively
generate disulfides and cysteic acid residues, respectively, and could be used to
generate stocks of specific HMGB1 proteoforms. The extent of the oxidative
98

reactions and precise oxidation state of exposed HMGB1 could then be
determined using methods described within this thesis. The receptor affinity of
unique HMGB1 proteoforms could be measured with in vitro ligand binding assays
ranging from simple immunoprecipitation supernatant depletion to more
complicated isothermal titration calorimetry (ITC). Differences in Kd for proteoform
binding to receptors like RAGE, TLR 2, 4 & 9 and CXCR4 may point towards the
biological function of each proteoform. Functional assays will be required to
demonstrate the significance of in vitro binding affinity differences and could be
performed first in cell models and then eventually animal models.
A range of cell culture-based functional assays for HMGB1 proteoforms will
be required to fully characterize HMGB1 proteoform behavior. Non-immune cells
like hepatocytes could be used to determine the autocrine activity of HMGB1
proteoforms; endpoints like cell viability, changes in gene transcription,
morphological differentiation and growth could all be measured in response to
addition of HMGB1 proteoforms in the cell media. Inclusion of HMGB1 proteoforms
in the media during toxicity experiments, like APAP-overdose modeling, would
describe the contribution of proteoforms’ autocrine signaling to toxicity. Immune
cells could similarly be exposed to HMGB1 proteoforms and differences in cytokine
release, motility and differentiation could all be used to determine the type and
degree of immune stimulation each proteoform induces. Techniques like threedimensional spheroid cell culture may be required depending on the endpoint and
required amount of in vivo environment recapitulation. Assuming differential
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proteoform response is observed in cell culture experiments, animal models can
be used for a characterization of the systemic response to HMGB1 proteoforms.
Exposure in healthy control and animals undergoing acute oxidative pathology will
help elucidate the context dependence of HMGB1 proteoform function.
5b3. Measurement of HMGB1 Proteoform Abundance in Other Contexts
In addition to direct functional testing of HMGB1 proteoforms, characterizing
which HMGB1 proteoforms are present in which contexts in vivo will help to
illustrate the biological role of each. HMGB1 is present in platelets37-39 and other
white blood cells40-42 and as such, is secreted during the clotting process when
serum is prepared. The study of circulating HMGB1 will therefore have to be done
in plasma and any previous publications where HMGB1 analysis was done in
serum must be ignored. The presence and relative abundance of circulating
HMGB1 could be measured in various conditions by methods described within this
thesis, with the goal of identifying proteoforms unique to certain contexts or relative
enrichment of proteoforms in certain contexts. HMGB1 proteoform abundance in
pathological conditions involving acute oxidative stress, like APAP overdose,
ischemia-reperfusion injury and myocardial infarction, could be compared to that
of conditions involving chronic general inflammation, like rheumatoid arthritis or
gout. Such analysis may help to clarify which HMGB1 proteoforms are released
from activated immune cells and which are released from injured tissue as well as
determine the biomarker potential of each proteoform. Study of HMGB1
proteoforms over time in a given pathological context may also provide information
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if specific proteoforms can be correlated with distinct phases of immune response.
For example, consistent appearance of intermolecular disulfide HMGB1 during
peak cytokine release may indicate a causative role of the proteoform and motivate
further investigation.
5b4. Application of Oxidative Proteoform Analysis Other Proteins
The 2D-Nano-UHPLC-PRM/HRMS methods described within this thesis
were developed to characterize HMGB1 oxidation behavior but could easily be
adapted for similar characterization of other oxidation sensitive proteins of interest.
HMGB1 has multiple cysteine residues in important functional domains, is exposed
to oxidants in several pathological contexts and goes on to influence the immune
response to said pathology. Other proteins with similar characteristics would be
most interesting to analyze via LC-MS as they represent potential oxidative
biomarkers and could inform on the coordination of the immune response to
pathology. The Protein Kinase C (PKC) family, for example, is a family of proteins
involved in several important intracellular signaling pathways 110. PKC family
proteins all contain at least one zinc finger motif in the protein’s regulatory domain,
with each zinc finger containing six cysteine residues that make regulation of the
PKC protein sensitive to oxidation111. Applying methods described here to
characterize PKC oxidation may provide insight into how important functions like
metabolism are regulated through oxidation.
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Appendix: Supplementary Data
Table S1. PRM schedule for endogenous and SILAC internal standard HMGB2
peptides used for absolute HMGB1 quantitation (K* = acetyl lysine, K =

13C 15N
6
2

lysine and Y = 13C915N1 tyrosine).
Peptide Sequence

Precursor
Ion charge

Precursor
Ion (m/z)

27

40

3+

629.9897

27

40

3+

638.0039

H K*K*K*HPDASVNFSE

H K*K*K*HPDASVNFSE
57

61

2+
2+

K* GK*FE
57
61
K* GK*FE
146

153

2+

548.3617

146

153

2+

564.3901

2+

550.8608

2+

570.8963

K*

K*

349.7032
357.7174

K*AAK*LK*E

K*AAK*LK*E

K*

K*

180

186

SK*K*K*K*E

180

186

SK*K*K*K*E
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Product Ion
Charge

Product
Ion

2+
2+
2+
2+
2+
2+

b10
b12
b13
b10
b12
b13

647.3484
753.9041
827.4383
659.3697
765.9254
839.4596

1+
1+

b3
b3

404.2775
420.3059

1+
1+
1+
1+
1+
1+

y2
b5
b6
y2
b5
b6

321.1848
662.4546
775.5386
329.1990
686.4972
799.5812

1+
1+
1+
1+
1+
1+

y2
b4
b5
y2
b4
b5

321.1848
607.4124
780.5367
329.1990
631.4550
812.5935

Product Ion
(m/z)

Table S2. PRM schedule for endogenous (light) Cys-containing HMGB1 peptides
(CAE = carbamidoethyl cysteine, O3H = cysteic acid).
Precursor
Ion charge

Peptide Sequence

13

24

13

24

M SSYAFFVQTC[CAE]R

M SSYAFFVQTC[O3H]R

41

47

41

47

F SKKC[CAE]SE

F SKKC[O3H]SE

3+

3+

2+

2+

97

112

97

112

R PPSAFFLFC[CAE]SEYRPK

R PPSAFFLFC[O3H]SEYRPK

2+

2+

Precursor
Ion (m/z)

Product Ion
Charge

Product
Ion

509.5637

1+
1+
1+
1+

y8
y7
y6
b2

1042.5139
971.4767
824.4083
235.0747

501.8796

1+
1+
1+
1+

y6
y5
y3
b2

801.3560
654.2876
427.1606
235.0747

495.2476

1+
1+
1+
1+

y2
b3
b4
b5

235.0925
408.2321
581.3564
378.2050

483.7214

1+
1+
1+
1+

y3
y2
y5
b3

386.0864
235.0925
732.3351
408.2321

1008.5116

1+
1+
1+
1+

y7
y6
b7
b8

953.4509
779.4046
803.4199
916.5039

996.98546

1+
1+
1+
1+

y8
y2
b6
b7

1077.4670
244.1656
656.3515
803.4199
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Product Ion
(m/z)

Table S3. PRM schedule for SILAC internal standard (heavy) Cys-containing
HMGB1 peptides (CAE = carbamidoethyl cysteine, O3H = cysteic acid, K =
13C 15N ]
6
2

lysine and Y = 13C915N1 tyrosine).
Precursor
Ion charge

Peptide Sequence

13

24

13

24

M SSYAFFVQTC[CAE]R

M SSYAFFVQTC[O3H]R

41

47

41

47

3+

3+

2+

F SKKC[CAE]SE

F SKKC[O3H]SE

97

R PPSAFFLFC[CAE]SEYRPK

2+

112

R97PPSAFFLFC[O3H]SEYRPK112

2+

2+

Precursor
Ion (m/z)

Product Ion
Charge

Product
Ion

512.9061

1+
1+
1+
1+

y8
y7
y6
b2

1042.5139
971.4767
824.4083
235.0747

505.2220

1+
1+
1+
1+

y6
y5
y3
b2

801.3560
654.2876
427.1606
235.0747

503.2618

1+
1+
1+
1+

y2
b3
b4
b5

235.0925
416.2463
597.3848
386.2192

491.7356

1+
1+
1+
1+

y3
y2
y5
b3

386.0864
235.0925
374.6854
416.2463

1017.5324

1+
1+
1+
1+

y7
y6
b7
b8

971.4924
797.4461
803.4199
916.5039

1006.0062

1+
1+
1+
1+

y8
y2
b6
b7

1095.5084
252.1798
656.3515
803.4199
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Product Ion
(m/z)

Response Ratio (to APAP ITSD)

Response Ratio (to APAP-ITSD)
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Figure S1. Calibration curves for quantitation of APAP metabolites APAPglucuronide (APAP-G) and APAP-sulfate (APAP-S) constructed in Williams E
media. The ratio of metabolite signal to isotopically labeled internal standard

13C

3

APAP signal was plotted against APAP metabolite concentration. The slope,
intercept and regression coefficient (r2) are shown in each figure.
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Figure S2. HMGB1 calibration curves constructed in minimal essential media.
(A) H27KKKHPDASVNFSE40, (B) K57GKFE61, (C) K146KAAKLKE153 and (D)
K180SKKKKE186 were plotted against total peptide (ng). The slope, intercept and
regression coefficient (r2) are shown in each figure.

Figure S3. Product ion spectrum of MH22+ (m/z 763.8420) from HMGB1 tryptic
peptide M[O]13SSYAFFVQTC[CAE]R24 isolated from APAP-treated HepaRG cell
media. SILAC Internal Standard = [13C615N2] lysine (K) and [13C915N1] tyrosine (Y),
CAE = carbamidoethyl cysteine.
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FSKKC[CAE]SE

b4+

y2+

FSKKC[CAE]SE
SILAC Internal Standard

b4++
b4+

b5+
b5+

b6+

Figure S4. Product ion spectrum from collision-induced dissociation (CID) of
MH22+ (m/z 495.2476) from HMGB1 tryptic peptide F41SKKC[CAE]SE47 isolated
from APAP-treated HepaRG cell media. SILAC Internal Standard = [13C615N2]
lysine (K) and [13C915N1] tyrosine (Y), CAE = carbamidoethyl.

RPPSAFFLFC[CAE]SEYRPK

y7+

b7+

y7+

RPPSAFFLFC[CAE]SEYRPK
SILAC Internal Standard

y6+

y6+
y8+

y8+

b6+

b6+

b8+ y4+
b7++
y2+

b8++

y8++

b7++
y9+
b10+

y2+
b11+

y9+
y10+

Figure S5. Product ion spectrum from CID of MH22+ (m/z 1008.5116) from HMGB1
tryptic peptide R97PPSAFFLFC[CAE]SEYRPK112 isolated from APAP-treated
HepaRG cell media. SILAC Internal Standard = [13C615N2] lysine (K) and [13C915N1]
tyrosine (Y), CAE = carbamidoethyl.
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b6
b6+

b7+
y7+

y8+

Figure S6. Product ion spectrum from CID of MH22+ (m/z 996.9855) from HMGB1
tryptic peptide R97PPSAFFLFC[O3H]SEYRPK112 from APAP-treated HepaRG cell
media. O3H = cysteic acid.
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y3+

b6+

b5+
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b8+
y7+

y8+

b9+

y9+

Figure S7. Product ion spectrum from CID of MH22+ (m/z 996.9855) from the
synthetic tryptic peptide R97PPSAFFLFC[O3H]SEYRPK112. O3H = cysteic acid.
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b7-*

RPPSAFFLFCSEYRPK

b8-*

CEG

b6-*
y6-*

b8-*

y4-*

b7-*
y5-*
b9-*

Figure S8. Product ion spectrum of MH22+ (m/z 972.9931) from tryptic peptide
R97PPSAFFLFCSEYRPK112 containing Cys106-disulfide-linked to GSH (CEG)
prepared by oxidization of recombinant HMGB1 with chloramine-T in the presence
of 0.5 mM GSH (disulfide bond represented by dash with fragment on either side
described as normal, p = full peptide from respective side of disulfide, * = complete
loss of peptide).
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y8-p

M[O]SSYAFFVQTCR
CSER

y10-p

y7-p

y9-p

b2-*

y11-p
y6-p

y5-p
y4-p
b11-p

Figure S9. Product ion spectrum of MH22+ (m/z 973.9133) from HMGB1 tryptic
peptide M[O]13SSYAFFVQTCR24 with Cys23-Cys45-disufide cross-link.

The

peptide was prepared by oxidizing recombinant HMGB1 with chloramine-T in the
presence of 0.5 mM GSH (disulfide bond represented by dash with fragment on
either side described as normal, p = full peptide from respective side of disulfide, *
= complete loss of peptide).
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